3URGXFW(WDQHUFHSW
3URWRFRO1XPEHU
'DWH$XJXVW 3DJHRI
&21),'(17,$/7LWOH$0XOWLFHQWHU'RXEOH EOLQG5DQGRPL]HG&RQWUROOHG6WXG\ RI(WDQHUFHSWDQG
0HWKRWUH[DWHLQ&RPELQDWLRQRUDV0RQRWKHUDS\LQ6XEMHFWV:LWK 3VRULDWLF
$UWKULWLV
$PJHQ3URWRFRO1XPEHU(WDQHUFHSW
(XGUD&71XPEHU
&OLQLFDO6WXG\6SRQVRU $PJHQ,QF
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$

8QLWHG6WDWHV$GGUHVV

.H\6SRQVRU&RQWDFWV
2QH$PJHQ&HQWHU'ULYH7KRXVDQG2DNV&$

7HOHSKRQH
HPDLO
'DWH -XO\
$PHQGPHQW 0D\
6XSHUVHGLQJ$PHQGPHQW -XO\$PHQGPHQW
$PHQGPHQW2FWREHU
$XJXVW
&RQILGHQWLDOLW\1RWLFH
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDOLQIRUPDWLRQRI$PJHQ,QF
7KLVGRFXPHQWPXVWQRWEHGLVFO RVHGWRDQ\RQHRWKHUWKDQWKHVL WHVWXG\VWDIIDQG
PHPEHUVRIWKHLQVWLWXWLRQDOU HYLHZERDUGLQGHSHQGHQWHWKLFVFR PPLWWHHLQVWLWXWLRQDO
VFLHQWLILFUHYLHZERDUGRUHTXLYDOHQW
7KHLQIRUPDWLRQLQWKLVGRFXPHQWFDQQRWEHXVHGIRUDQ\SXUSRVH RWKHUWKDQWKH
HYDOXDWLRQRUFRQGXFWRIWKHFOLQLFDOLQYHVWLJDWLRQZLWKRXWWKH SULRUZULWWHQFRQVHQWRI
$PJHQ,QF 
,I\RXKDYHTXHVWLRQVUHJDUGL QJKRZWKLVGRFXPHQWPD\EHXVHGR UVKDUHGFDOOWKH
$PJHQ0HGLFDO,QIRUPDWLRQQXPEHUIRU86VLWHV$0*( 1IRU&DQDGLDQ
VLWHV$0*(1IRUDOORWKHUFRXQWULHV )RUDOORWKHU
VWXG\UHODWHGTXHVWLRQVFRQWLQXHWRFRQWDFWWKH.H\6SRQVRU&R QWDFW[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY
Product:  Etanercept  
Protocol Num ber:  20130207  
Date:  [ADDRESS_1075662] 2016  Page 2 of 76 
CONFIDENTIAL  Investigatorâ€™s Agreement  
I have read the attached protocol entitled A Multicenter Double-Blind, Randomized 
Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in 
Subjects W ith Psoriatic Arthritis , dated [ADDRESS_1075663] 2016 , and agree to abide by [CONTACT_32662]. 
I agree to comply with the International Conference on Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice  (GCP) and applicable national or regional 
regulations/guidelines . 
I agree to ensure that Financial Disclosure Statements will be completed by: 
â€¢me (including, if applicable, my spouse [or legal partner] and dependent children)
â€¢my subinvestigators (including, if applicable, their spouses [or legal partners] and
dependent children)
at the start of the study and for up to one year after the study is completed, if there are 
changes that affect my financial disclosure status. 
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of [COMPANY_010] Inc.  
Signature  
[CONTACT_53440] (DD Month YYYY)  
Product:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075664] 2016 Page 3 of 76 
CONFIDENTIALProtocol Synopsis 
Title:   A Multicenter Double-Blind, Randomized Co ntrolled Study of Etanercept and Methotrexate 
in Combination or as Monotherapy in Subjects With Psoriatic Arthritis   
Study Phase:   Phase 3 
Indication:   Psoriatic Arthritis (PsA) 
Primary Objective:   To evaluate the efficacy of etaner cept plus methotrexate therapy and 
etanercept monotherapy compared to methotrexate monotherapy, in subjects with PsA as 
measured by [CONTACT_782258] (ACR) 20 response at week 24. 
Key Secondary Objective:  To evaluate the efficacy of etanercept plus methotrexate therapy 
and etanercept monotherapy compared to met hotrexate monotherapy as measured by [CONTACT_782259] l Disease Activity (MDA) at week 24. 
Other Secondary Objectives: 
To evaluate the efficacy of etanercept plus me thotrexate therapy and etanercept monotherapy 
compared to methotrexate monotherapy on the following:  
ï‚·Other measures of arthritis activity
ï‚·Measures of non-arthritic PsA disease activity
ï‚·Key patient reported outcomes (PRO) related to physical function and quality of life
Safety Objectives: ï‚·To evaluate the safety of etanercept and methotrexate
Hypotheses:   Primary:  Etanercept plus methotrexa te therapy and etanercept monotherapy are 
more efficacious than methotrexate monotherapy as  measured by [CONTACT_782260] 20 response at week 24. 
Secondary:  Etanercept plus methotrexate therapy and etanercept monotherapy are more 
efficacious than methotrexate as measured by [CONTACT_782261] 24. Primary Endpoint:  ACR 20 response at week 24 
Key Secondary Endpoint:  MDA response at week 24  
Other Secondary Endpoints:  
ï‚·Modified Nail Psoriasis Severity Index (modified NAPSI) score and change from baseline at
week 24 
ï‚·Leeds dactylitis score and change from baseline at week 24
ï‚·Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis score and change
from baseline at week 24
ï‚·ACR 20 response at all other measured timepoints
ï‚·MDA response at all other measured timepoints
ï‚·Psoriatic Arthritis Disease Activity Sc ore (PASDAS) at all measured timepoints
ï‚·ACR 50, ACR 70, and components of ACR at all measured timepoints
ï‚·Simplified Disease Activity Index (SDAI)  and change from baseline at all measured
timepoints
ï‚·Clinical Disease Activity Index (CDAI) and change from baseline at all measured timepoints
ï‚·Disease activity score (28 joint) using th e C-reactive protein formula (DAS28-CRP) and
change from baseline at all measured timepoints
Product:  Etanercept  
Protocol Num ber:  20130207  
Date:  [ADDRESS_1075665] 2016  Page 4 of 76 
CONFIDENTIAL    â€¢ Disability Index of the Health Assessment Questionnaire (HAQ -DI) score and change from 
baseline at week 24  
â€¢ Medical Outcomes Short Form -36 Questionnaire ( SF-36) score and change from baseline at 
week 24  
For subjects with involved body surface area (BSA)  â‰¥ 3% at baseline:  
â€¢ Static Physician Global Assessment of Psoriasis ( sPGA)  at week 24  
â€¢ BSA at week 24  
Safety Endpoints : 
â€¢ Adverse events  
â€¢ Serious adverse events  
â€¢ Laboratory parameters and vital signs 
Study Design:   This is a multicenter, randomized, double -blind controlled study in subjects with 
PsA.  The study will consist of a 30- day screening period, a 48- week double- blind treatment 
period and a 30- day safety follow -up period.  Approximat ely 840 subjects will be randomly 
assigned in a 1:1:1 ratio to one of three treatment groups (280 per group):  etanercept [ADDRESS_1075666].  
Sample Size:   Approximat ely [ADDRESS_1075667] Eligibility Criteria:   Subjects must be adults with active PsA  based on the 
Classification Criteria for Psoriatic Arthritis (CASPAR)  who are naÃ¯ve to etanercept and other 
biologics and have no prior use of methotrexate for the treatment of PsA.   Prior  treatment with 
methotrexate is allowed if indicated for psoriasis as long as discontinuation was not due to toxicity 
or intolerance and treatment was discontinued â‰¥ [ADDRESS_1075668] Dosage and Administration:   Etanercept dosing in the 
planned study follows the recommended label dosing for subjects with PsA.  Etanercept will be 
provided as a [ADDRESS_1075669] Dosage and Administration:   Methotrexate dosing will 
begin at a dose of [ADDRESS_1075670]  Dosage and Administration:   Folic acid dosing will 
be [ADDRESS_1075671] of care. See Section 6.3.1 . 
Procedures:   Written informed consent must be obtained from all subjects before any screening 
procedures are performed.  The following procedures will occur per the Schedule of 
Assessments:  medical and medication history, physical examination, physical  measures, vital 
signs, adverse event and concomitant medication assessment, tuberculosis testing, pregnancy testing, urinalysis, and blood draw for serum chemistry, hematology, hepatitis B and C testing, 
Product:  Etanercept  
Protocol Num ber:  20130207  
Date:  [ADDRESS_1075672] of study procedures, including the timing of each 
procedure, please refer to Secti on 7 and the Schedule of Assessments  (Table  1). 
Statistical Considerations:   The primary analysis will occur after all data through week [ADDRESS_1075673] between etanercept plus methotrexate therapy and methotrexate monotherapy and between etanercept monotherapy and methotrexate monotherapy will be tested in a Bonferroni -based gatekeepi[INVESTIGATOR_782243] -wise 2 -sided type one error rate at 0.05.  Between treatment comparisons will be made 
using the stratified Cochran- Mantel -Haenszel (CMH) test with baseline body mass index and prior 
non-biologic disease modifying antirheumatic drug ( DMARD ) use as the stratification factors.  All 
other efficacy endpoints will be tested at a significance level of 0.05 without adjusting for multiplicity.  Safety endpoints will be summarized descriptively based on the safety analysis set.  For a full description of statistical analysis methods, please refer to Section 10
. 
Sponsor:   [COMPANY_010] Inc  
Data Element Standards Version(s)/Date(s):  Version 4.[ADDRESS_1075674]:  Etanercept  
Protocol Number:  20130207  
Date:  [ADDRESS_1075675]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075676] 2016  Page 7 of 76 
CONFIDENTIAL  Study Glossary  
Abbreviation or Term  Definition/Explanation  
eSAE contingency form  electronic serious adverse event contingency form  
ACR  American College of Rheumatology  
ALT Alanine aminotransferase  
ALP Alkaline phosphatase  
AST Aspartate aminotransferase 
BMI Body mass index  
BSA Body Suface Area  
CASPAR  Classification Criteria for Psoriatic Arthritis  
CDAI  Clinical disease activity index  
CMH  Cochran -Mantel -Haenszel  
eCRF Electronic  case report form  
CRP  C-reactive protein  
DAS28 -CRP  Disease activity score (28 joint) using the C -reactive protein formula 
DILI Drug-induced liver injury  
DMARD  Disease modifying antirheumatic drug  
DNA  Deoxyribonucleic acid  
EDC  Electronic data capture  
Electronic Source Data 
(eSource)  Source data captured initially into a permanent electronic record 
used for the reconstruction and evaluation of a trial.  
End of Follow -up Defined as when the last subject completes the last 
protocol -specified assessment  in the study   
EOS End of study for individual subject defined as the last day that protocol -specified procedures are conducted for an individual subject  
End of Study (end of trial)  The time when the last subject is assessed or receives an intervention for evaluation in the study.  
End of Treatment (EOT)  Defined as the last assessment for the protocol -specified treatment 
phase of the study for an individual subject  
ET Early termination  
FDA Food and Drug Administration  
GCP  Good clinical practice  
GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis  
HAQ -DI Disability Index of the Health Assessment Questionnaire  
HBV  Hepatitis B virus 
HCP  Health care provider  
ICH International Conference on Harmonisation  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075677] 2016  Page 8 of 76 
CONFIDENTIAL    Abbreviation or Term  Definition/Explanation  
Interactive Voice 
Response System (I XRS) Telecommunication technology that is linked to a central computer in real time as an interface to collect and process information.  
IPIM Investigational product instruction manual  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
MIPA study Methotrexate in Psoriatic Arthritis Study  
MDA  Minimal Disease Activity  
Modified NAPSI  Modified Nail Psoriasis Severity Index  
van der Heijde mTSS  van der Heijde Modified Total Sharp Score  
NSAID  Non-steroidal anti -inflammatory drug  
PASDAS Psoriatic Arthritis Disease Activity Score  
PCR  Polymerase chain reaction 
PFS Pre-filled syringe  
PI [INVESTIGATOR_782244]-[ADDRESS_1075678](s)/protocol required therapi[INVESTIGATOR_33217]/are administered to the subject  
TBL  Total bilirubin  
TNF Tumor necrosis factor  
ULN Upper limit of normal  
VAS Visual analog scale  
WBC  White blood cells  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075679] 2016  Page 9 of 76 
CONFIDENTIAL  Table of Contents 
Protocol Synopsis  ............................................................................................................. 3  
Study Design and Treatment Schema  .............................................................................. 6  
Study Glossary  .................................................................................................................. 7  
1. OBJECTIVES ......................................................................................................... 14
1.1 Primary ....................................................................................................... 14 
1.2 Key Secondary Objective ........................................................................... 14 
1.3 Other Secondary Objectives  ....................................................................... 14 
1.4 Safety
 Objectives  ........................................................................................ 14 
1.5 Exploratory Objectives  ................................................................................ 14 
2. BACKGROUND AND RATIONALE  ........................................................................ 14
2.1 Disease  ....................................................................................................... 14 
2.2 Etanercept (EnbrelÂ®) Background  .............................................................. [ADDRESS_1075680] Background:  Methotrexate ....................... [ADDRESS_1075681] ENROLLMENT  ..................................................................................... 23
5.1 Randomization/Treatment Assignment ...................................................... 24 
5.2 Site Personnel Access to Individual Treatment Assi
gnments  .................... 24 
6. TREATMENT PROCEDURES  ............................................................................... 25
6.1 Classification of Products and/or Medical Device(s)  .................................. [ADDRESS_1075682]:  Etanercept  .............................. 25 
[IP_ADDRESS] Dosage, Administration, and Schedule .................... [ADDRESS_1075683]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075684]:  Methotrexate ................... 26 
[IP_ADDRESS] Dosage, Administration, and Schedule .................... 26 
[IP_ADDRESS] Dosage Adjustments, Delays, Rules for 
Withholding or Restarting, Permanent 
Discontinuation ........................................................ [ADDRESS_1075685]:  Folic Acid ................. [ADDRESS_1075686] Complaints  .................................................................................... 29 
6.8 Excluded Treatments and/or Procedures During Study Period .................. 29 
6.9 Contraceptive Requirements  ...................................................................... 30 
7. STUDY PROCEDURES  ......................................................................................... 31 
7.1 Schedule of Assessments  .......................................................................... 31 
7.2 General Study Procedures  ......................................................................... 34 
7.2.1 Screening ................................................................................... 34 
7.2.2 Re-screening .............................................................................. 34 
7.2.3 Baseline Visit (Day 1)  ................................................................. [ADDRESS_1075687] End of Treatment/Early Termination .............................. 35 
7.2.7 Safety Follow -up/End of Study  ................................................... 35 
7.3 Description of Study Assessments and Procedures  ................................... 35 
7.3.1 Informed Consent  ....................................................................... 36 
7.3.2 Demographic Data ......................................................................  36 
7.3.3 Medical History  ........................................................................... 36 
7.3.4 Medication History  ......................................................................  36 
7.3.5 Physical Examinati
on ................................................................. 36 
7.3.6 Physical Measurement ............................................................... 36 
7.3.7 Vital Signs  ................................................................................... 37 
7.3.8 PsA Disease Assessments ......................................................... 37 
[IP_ADDRESS] Swollen/Tender Joint Counts  ................................... 37 
[IP_ADDRESS] Leeds Dactylitis Index  .............................................. [ADDRESS_1075688]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075689] 2016  Page 11 of 76 
CONFIDENTIAL    [IP_ADDRESS] Spondyloarthritis Research Consortium of 
Canada Enthesitis Index  .......................................... 38 
[IP_ADDRESS] Radiographs  ............................................................. 38 
7.3.9 Psoriasis Disease Assessments ................................................. 39 
[IP_ADDRESS] Static Physician Global Assessment of Psoriasis .................................................................. 39 
[IP_ADDRESS] Body Surface Area Involvement  .............................. 39 
[IP_ADDRESS] Modified Nail Psoriasis Severity Index  ..................... 39 
[IP_ADDRESS] Physician Global Assessment of Disease 
Activity  ...................................................................... 40 
7.3.10 Patient Reported Outcomes  ....................................................... 40 
[IP_ADDRESS] Patient Global Assessment of Joint Pain ................. 40 
[IP_ADDRESS] Patient Global Assessment of Disease 
Activity  ...................................................................... 40 
[IP_ADDRESS] Disability Index of the Health Assessment Questionnaire ........................................................... 40 
[IP_ADDRESS] Medical Outcomes Short Form -36 
Questionnaire ........................................................... 40 
7.4 Laboratory Assessments  ............................................................................ 41 
7.4.1 Tuberculosis Testing  .................................................................. 42 
[IP_ADDRESS] [COMPANY_003] .......................................................................... 42 
[IP_ADDRESS] Quantiferon .............................................................. [ADDRESS_1075690] ................................................................. 43 
7.5 Biomarker Development  ............................................................................. 43 
7.6 Pharmacogenetic Studies  ........................................................................... 43 
7.7 Sample Storage and Destruction  ................................................................ 43 
8. WITHDRAWAL FROM TREATMENT, PROCEDURES, AND STUDY  .................. 45 
8.1 Subjectsâ€™ Decision to Withdraw .................................................................. 45 
8.2 Investigator or Sponsor Decision to Withdraw or Terminate Subjectsâ€™ Participation Prior to Study Completion ...................................... [ADDRESS_1075691]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075692] 2016  Page 12 of 76 
CONFIDENTIAL    10. STATISTICAL CONSIDERATIONS  ....................................................................... 50 
10.1 Study Endpoints, Analysis Sets, and Covariates  ........................................ 50 
10.1.1 Study Endpoints  ......................................................................... 50 
[IP_ADDRESS] Primary Endpoint ..................................................... 50 
[IP_ADDRESS] Key Secondary Endpoint ......................................... 50 
[IP_ADDRESS] Other Secondary Endpoints  ..................................... 50 
[IP_ADDRESS] Safety Endpoints  ...................................................... 51 
[IP_ADDRESS] Exploratory Endpoints .............................................. 51 
10.1.2 Analysis Sets  .............................................................................. 51 
[IP_ADDRESS] Full Analysis Set ...................................................... 51  
[IP_ADDRESS] Psoriasis Efficacy Analysis Set  ................................ 52 
[IP_ADDRESS] Safety Analysis Set .................................................. [ADDRESS_1075693]/Independent Ethics Committee  ........................ [ADDRESS_1075694]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075695]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075696] 2016  Page 14 of 76 
CONFIDENTIAL    1. OBJECTIVES  
1.1 Primary 
To evaluate the efficacy of etanercept plus  methotrexate therapy and etanercept 
monotherapy compared to methotrexate monotherapy, in subjects with psoriatic 
arthritis  (PsA) as measured by [CONTACT_782262] (ACR) 20 response at week  24. 
1.2 Key Secondary  Objective 
To evaluate the efficacy of etanercept plus  methotrexate therapy and etanercept 
monotherapy compared to methotrexate monotherapy as measured by [CONTACT_782263] (MDA) at week 24. 
1.3 Other Secondary Objectives 
To evaluate the efficacy of etanercept plus  methotrexate therapy and etanercept 
monotherapy compared to methotrexate monotherapy on the following:  
â€¢ Other measures of arthritis activity  
â€¢ Measures of non-arthritic PsA disease activity  
â€¢ Key patient reported outcomes  (PRO) related to physical function and quality of life  
1.4 Safety Objectives 
To evaluate the safety of etanercept and methotrexate. 1.5 Exploratory Objectives 
To evaluate the efficacy of etanercept plus methotrexate therapy and etaner cept 
monotherapy compared to methotrexate monotherapy on the following:  
â€¢ Other measures of disease activity including the skin  
â€¢ Other PROs  
â€¢ Inhibition of radiographic progression as measured by [CONTACT_941] v an der Heijde modified 
Total Sharp score (mTSS) for PsA 
â€¢ To investigate potential biomarkers of disease activity and response to etanercept. 
â€¢ To investigate the effects of genetic variation in disease genes and drug target genes 
on PsA  and/or subject response to etanercept.  
2. BACKGROUND AND RATIONALE  
2.1 Disease 
PsA is a chronic inflammatory disorder of the peripheral joints and axial skeleton that 
occurs in 7
% to 34 % of patients with psoriasis (Scarpa et al, 1984; Biondi et al, 1989; 
Espi[INVESTIGATOR_198031], 1992; Shbeeb et al, 2000), which in turn has a prevalence of 1 % to 3% in 
the general population ( Biondi et al, 1989; Koo, 1996).  Articular involvement can vary 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075697] associated psoriasis, PsA can present without skin changes.  Radiographic features include joint erosions, joint space loss, osteolysis that may cause penciling of the phalanx, and periostitis.  PsA can lead to permanent destruction of joints and functional disabil ities. 
2.2 Etanercept (Enbrel
Â®) Background 
Tumor Necrosis Factor ( TNF) is a naturally occurring cytokine that is involved in normal 
inflammatory and immune responses.  It plays a role in the inflammatory process of plaque psoriasis.  Elevated levels of TNF are found in involved tissues and fluids of patients with rheumatoid arthritis, PsA, ankylosing spondylitis, and plaque psoriasis.  Two distinct receptors for TNF, a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75), exist naturally as monomeric molecules on cell surfaces and in soluble 
forms. Biological activity of TNF is dependent upon binding to either c ell surface 
TNF receptor.  Etanercept is a dimeric fusion protein consisting of the extracelluar 
ligand-binding portion of the human 75 kilodalton TNF  receptor linked to the Fc portion of 
human IgG1.  Etanercept inhibits binding of TNF-Î± and TNF- Î² (lymphotoxin alpha 
[LT-Î± ]) to cell surface TNF receptors , rendering TNF biologically inactive. 
In many countries, etanercept is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function 
in patients with PsA.   
Etanercept is also indicated for the treatment of:  (1) moderately to severely active 
rheumatoid arthritis; (2) moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 and older; (3) psoriatic arthritis; (4) active ankylosing 
spondylitis; and ( 5) adult patients with chronic moderate to severe plaque psoriasis.  
Refer to the specific section of the Investigatorâ€™s Brochure or product label for additional information related to physical, chemical, and pharmaceutical properties and formulations. 
2.[ADDRESS_1075698] Background:  Methotrexate 
Methotrexate is an antimetabolite used in the treatment of certain neoplastic diseases, 
psoriasis, and rheumatoid arthritis .  Methotrexate or its metabolites inhibit dihydrofolic 
acid reductase and antagonize thymidylate synthase.  Methotrexate is thought to inhibit 
5-aminoimidazole 4-carboxamide ribonucleotide transformylase which leads to an 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075699] commonly used non-biologic disease modifying antirheumatic drug (DMARD) in 
PsA.  Although the use of methotrexate is standard therapy in the medical community 
and it is mentioned in guidelines in the treatment of PsA, it is not an approved drug for 
the treatment of PsA in many countries . 
Refer to the regional manufacturer package insert for additional information. 
2.[ADDRESS_1075700] recent randomized placebo- controlled trial of 
methotrexate in PsA is the Methotrexate in Psoriatic Arthritis (MIPA) study 
(Kingsley  et al, 2012).  This was a  6-month, double-blind, parallel -group study in  
methotrexate naÃ¯ve subjects randomized to receive methotrexate (15 mg/wk; n =  109) or 
placebo (n =  112).  In an intent-to-treat analysis, there were no statistically significant 
improvements in measures of disease activity across groups at 24 weeks.  The odds 
ratios (95 % CI) for  Psoriatic Arthritis Response Criteria, ACR 20, and Disease activity 
score (28 joint) responders for the methotrexate and placebo groups were 1.77 (0.97, 
3.23; p = 0.06), 2.00 (0.65, 6.22; p = 0.23), and 1.70 (0.90, 3.17; p = 0.10), respectively.  
In a completer analysis, percent responders for methotrexate and placebo were 34 % and 
21% for ACR  20 respectively  for a difference of 13 %.  In the PsA pi[INVESTIGATOR_16076], ACR 20 
response at week 24 was 50 % and 1 4% in the etanercept and placebo groups 
respectively  for a difference of 36 %.  Nevertheless, comparisons with the MIPA trial need 
to be qualified by [CONTACT_782264][INVESTIGATOR_782245]Ã¯ve.  Furthermore, in the MIPA trial the target dose of 
methotrexate was  15 mg QW, a less than maximal clinically used dose level . 
In rheumatoid arthritis, combining TNF inhibitors such as etanercept with methotrexate 
leads to superior efficacy relative to each agent used alone (Klareskog et al , 2004).  The 
role of methotrexate in combination with etanercept in PsA remains unclear. Analysis of 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075701] longitudinal observational study 
showed no consistent differences in response over a 12-month period between patients 
who started their TNF inhibitor as monotherapy or in combination with methotrexate 
(Fagerli et al, 2014)  Similar findings were found in a [LOCATION_002] registry  
(Mease  et al, 2013) .  No difference was found in reaching clinical disease activity index 
(CDAI ) low disease activity or staying in low disease activity on anti -TNF monotherapy 
vs. combination with methotrexate in this study  (Mease et al , 2013).  These data suggest 
key differences in the response of PsA patients compared to RA patients to 
methotrexate and highlight the importance of characterizing the role of etanercept as a monotherapy agent in PsA. 
A new disease activity state called MDA, has been developed and validated 
(Coates  et al, 2010a and Coates et al , 2010b).  MDA  represents a low disease activity 
state and would further the â€˜treat-to- targetâ€™ approach in PsA.  The MDA criteria is specific 
for PsA and incorporates  measures of joint and entheseal inflammation, skin disease, 
PROs  and functional disability to assess the subjectâ€™s disease activity.  The results of  the 
validation analysis support the prognostic value of the PsA MDA criteria and show that 
subjects achieving MDA are more likely to have a better radiologic outcome 
(Antoni  et al, 2005a, Antoni et al, 2005b). 
This study will also aim to characterize the response rates of etanercept on enthesitis, 
dactylitis , and psoriatic nail changes.  The PRESTA trial , assesse d two different 
regimens of etanercept ( 50 mg twice weekly or 50 mg once weekly ) in subjects with 
psoriasis and PsA.  Etanercept 50 mg once weekly  resulted in a 70.0
% and 
81.3 % improvement from baseline in enthesitis at week 12 and 24 respectively.  
Similarly, improvement in dactylitis from baseline at weeks 12 and 24 were 78.4 % and 
84.8 %, respectively (Sterry et al, 2010).  There is a paucity of data regarding the efficacy 
of methotrexate monotherapy on dactylitis and enthesitis in patients with PsA.  A recent study looking at the effect of etanercept on the Nail Psoriasis Severity Index (NAPSI) 
score at week 12 and 24 improved by 50
% and 72 %, respectively on a weekly dose of 
Enbrel of 50 mgs (Ortonne et al, 2013).  In another recent study comparing improvement 
in nail changes on methotrexate monotherapy compared to cyclosporine monotherapy , 
methotrexate demonstrated a 30% improvement at 12 weeks and a 54 % improvement at 
24 weeks in the NAPSI score  (GÃ¼mÃ¼ÅŸel et al, 2011). 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075702] 2016  Page 18 of 76 
CONFIDENTIAL    2.5 Clinical Hypotheses 
Primary:  Etanercept plus methotrexate therapy and etanercept monotherapy are more 
efficacious than methotrexate monotherapy as measured by [CONTACT_782265] 20 response at week 24. 
Secondary:  Etanercept plus methotrexate therapy and etanercept monotherapy are 
more efficacious than methotrexate as measured by [CONTACT_782266] 24. 
3. EXPERIMEN TAL PLAN  
3.[ADDRESS_1075703] of a 30- day screening per iod, a 48-week randomized 
double-blind treatment period, and a 30-day safety follow-up period. 
Approximately 840 subjects will be randomly assigned in a 1:1:1 ratio to one of 
three treatment groups ( 280 per arm):  
â€¢ Etanercept 50 mg weekly by [CONTACT_177140] 20 mg 
weekly  
â€¢ Etanercept 50 mg weekly by [CONTACT_177143]   
â€¢ Oral methotrexate [ADDRESS_1075704] complete the procedures outlined for the disease assessment visit 
as described in Section 7.2.5 and Table 1 . 
3.1.2 Inadequate Response 
Inadequate response is defined by [CONTACT_7661] < 20
% improvement in their tender and < 20% 
in their swollen joint counts from baseline at or after week 24.  This will be calculated 
automatically based on the joint count.  Inadequate response may be assessed at a 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075705] complete a disease assessment follow-up 
visit 4 weeks later to monitor for labs (see Section 7.2.5 and Table 1 ).  
Subjects randomized to the etanercept plus methotrexate arm that have an inadequate 
response will continue to receive the same treatment. 
3.2 Number of Sites 
Approximately 105 sites globally  will participate in the study.  Additional sites may be 
added if necessary. Sites that do not enroll subjects within 3 months of site initiation may 
be closed.  
3.3 Number of Subjects 
Participants in this clinical investigation shall be referred to as â€œsubjectsâ€.  
The number of subjects expected to be enrolled in the study is [ADDRESS_1075706] ELIGIBILITY  
Investigators will be expected to maintain a screening log of all potential study candidates that includes limited information about the potential candidate (eg, date of screening) . 
Before any study specific activities/procedure, the appropriate written informed consent must be obtained (see Section 11.1 ). 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075707] has provided informed consent prior to initia tion of any study -specific 
activities/procedures.  
102. â‰¥ [ADDRESS_1075708] has had a diagnosis of PsA by [CONTACT_782267] (CASPAR) criteria 
104. subject has â‰¥ 3 tender and â‰¥ 3 swollen joints (as part of a 68/66 j oint count) at 
screening and at baseline 
105. subject has an active psoriatic skin lesion (at least one psoriatic plaque approximately 2 cm or more in diameter)  
106. subject is naÃ¯ve to etanercept and any other biologic for the treatment for PsA or psoriasis  
107. subject has no prior use of methotrexate for PsA. Prior treatment with 
methotrexate is allowed if indicated for psoriasis as long as discontinuation was 
not due to toxicity or intolerance and treatment discontinued 
â‰¥ [ADDRESS_1075709]  
108. for subjects receiving non-steroidal anti -inflammatory drugs ( NSAIDs ) (including 
as needed use [PRN]):  the dose must be stable for â‰¥ [ADDRESS_1075710]  
109. for subjects receiving oral corticosteroids:  the dose m ust be stable (not to 
exceed the equivalent of 10 mg of prednisone per day) for â‰¥ [ADDRESS_1075711] for hepatitis B surface antigen, hepatitis B core antibody and 
hepatitis C antibody  
111. no known history of active tuberculosis  
112. National guidelines should be followed for appropriate tuberculosis  screening in 
the setting of anti -TNF therapy, including a minimum of:  
â€¢ subject has a negative test for tuberculosis during screening defined as 
either: 
o negative puri fied protein derivative ([COMPANY_003]) ( < [ADDRESS_1075712] is placed) OR  
o negative Quantiferon test. 
subjects with a positive [COMPANY_003] and a history of Bacillus Calmette-GuÃ©rin vaccination are allowed with a negative Quantiferon test.  
subjects with a positive [COMPANY_003] test (without a history of Bacillus Calmette-GuÃ©rin vaccination) or subjects with a positive or indeterminate Quantiferon test are allowed if they have ALL of the following: 
â€¢ no symptoms per tuberculosis worksheet provided by [CONTACT_21931]. 
â€¢ documented history of a completed course of adequate treatment or 
prophylaxis per local standard of care prior to the start of investigational 
product  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075713] 2016  Page 21 of 76 
CONFIDENTIAL    â€¢ no known exposure to a case of active tuberculosis after most recent 
prophylaxis  
â€¢ no evidence of active tuberculosis on chest radiograph within [ADDRESS_1075714] 
â‰¤ [ADDRESS_1075715] at baseline (day 1)  
4.1.[ADDRESS_1075716] has any active infection (including chronic or localized infections) for which anti -infectives were indicated within [ADDRESS_1075717] has one or more significant concurrent medical conditions per investigator judgment, including the following: 
â€¢ poorly controlled diabetes  
â€¢ chronic kidney disease stage IIIb, IV, or V 
â€¢ symptomatic heart failure ([LOCATION_001] Heart Association class II, III, or IV)  
â€¢ myocardial infarction or unstable angina pectoris within the past 12 months 
prior to randomization 
â€¢ uncontrolled hypertension 
â€¢ severe chronic pulmonary disease (eg, requiring oxygen therapy)  
â€¢ multiple sclerosis or any other demyelinating disease 
â€¢ major chronic inflammatory disease or connective tissue disease other than 
PsA (eg, systemic lupus erythematosus with the exception of secondary 
Sjogrenâ€™s syndrome)  
Excluded Medications  
207. prior or current use of cyclophosphamide, chlorambucil, nitrogen mustard, or any 
other alkylating agent.  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075718] has used any of the following â‰¤ 3 months prior to screening:  
â€¢ abatacept  
â€¢ anakinra  
â€¢ azathioprine  
â€¢ cyclosporine  
â€¢ gold 
â€¢ mycophenolate mofetil  
â€¢ Prosorba column 
â€¢ Systemic tacrolimus  
â€¢ Otezla (apremilast) 
209. subject has used leflunomide â‰¤ [ADDRESS_1075719] has used any of the following  â‰¤ 4 weeks prior to screening: 
â€¢ sulfas alazine  
â€¢ intraarticular, intramuscular or intravenous corticosteroids, including 
adrenocorticotropic hormone 
â€¢ intraarticular hyaluronic acid injections  
â€¢ live vaccines  
211. for subjects not on continuous analgesics, subject has taken the following within 
12 hours prior to screening:  acetaminophen, NSAID, hydrocodone, codeine, tramadol, propoxyphene and/or oxycodone (unless in the form of oxycontin).  For subjects not on continuous analgesics, subject has taken oxycontin within 
[ADDRESS_1075720] has laboratory abnormalities during screening, including the following: 
â€¢ Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 x 
the upper limit of normal (ULN)  
â€¢ Platelet cou nt < 125,000/mm
3 
â€¢ White blood cell count <  3,000 cells /mm3 
â€¢ Absolute neutrophil count <  1500/mm3 
â€¢ Estimated creatinine clearance <  50 mL/min (Cockroft-Gault formula, calculated 
value to be provided to sites)  
213. Subject has any other laboratory abnormality, which, in the opi[INVESTIGATOR_492249] a safety risk, will prevent the subject from completing the 
study, or will interfere with the interpretation of the study results.  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075721] is not willing to use highly -effective methods  of birth control 
during treatment and for 6 months  after the end of treatment (except if at least 
2 years postmenopausal or surgically sterile [ hysterectomy, bilateral 
oophorectomy, or bilateral salpi[INVESTIGATOR_61502] ] or has had a bilateral tubal ligation). 
215. Male subject with a partner of child- bearing potential is not willing to use a 
condom  during treatment and for 6 months  after the end of treatment (except for 
men who are surgically sterile). 
216. Male subject with a pregnant partner, who is not willing to use a condom  to 
prevent exposure of the fetus to semen during treatment and for [ADDRESS_1075722]â€™s last visit and for 
[ADDRESS_1075723] likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all required study procedures (eg, PROs ) to 
the best of the subject and investigatorâ€™s knowledge. 
221. History or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opi[INVESTIGATOR_54485], if consulted, would pose a risk to subject safety 
or interfere with the study evaluation, procedures or completion. 
222. Currently receiving treatment in another investigational device or drug study, or 
participated in any study involving administration of an investigational drug or device within [ADDRESS_1075724] ENROLLMENT  
Before subjects begin participation in any study -specific activities/procedures, [COMPANY_010] 
requires a copy of the siteâ€™s written institutional review board /independent ethics 
committee (IRB/IEC ) approval of the protocol, informed consent form, and all other 
subject information and/or recruitment material, if applicable (see Section 11.2).  All 
subjects must personally sign and date the informed consent form before 
commencement of study -specific activit ies/procedures. 
A subject is considered enrolled when the investigator decides that the subject has met 
all eligibility criteria.  The i nvestigator is to document this decision and date, in the 
subjectâ€™s medical record and in the enrollment CRF. 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075725] who enters into the screening period for the study (defined as the point at 
which the subject signs the informed consent form ) receives a unique subject 
identification number before any study -related activities/procedures are performed.  The 
subject identification number, assigned by [CONTACT_782268] 
(IXRS ),  will be used to identify the subject throughout the clinical study and must be 
used on all study documentation related to that subject.  The subject identification number must remain constant throughout the entire clinical study; it must not be 
changed after initial assignment, including if a subject is re- screened.  This number will 
not necessarily be the same as the randomization number assigned for the study. 
Subjects not meeting eligibility criteria are permitted to re-screen twice  
(see Section  7.2.1 and 7.2.2). 
5.1 Randomization/Treatment Assignment  
Subjects that meet all el igibility criteria will be randomized at baseline to receive 
etanercept plus methotrexate, etanercept plus placebo for methotrexate or methotrexate 
plus placebo for etanercept in a 1:1:[ADDRESS_1075726]â€™s medical record and on the enrollment CRF.  
5.[ADDRESS_1075727]â€™s treatment assignment should only be unblinded when knowledge of the treatment is essential for the further management of the subject on this study .  In the 
event that a subjectâ€™s treatment assignment must be unblinded by [CONTACT_782269].  Refer to the 
Investigational Product Instruction Manual  (IPIM) for a  description regarding how 
responsible pharmacists and investigators will access treatment information via IXRS  in 
the event that there is a need to break the treatment blind. 
Other than rescue therapy situations, in the event of inadvertent unblinding (ie, the blind 
was not intended to be broken as described above), the investigator should immediately 
notify [COMPANY_010].  Each scenario will be reviewed individually to determine if the impacted 
subject(s) are able to continue receiving investigational product.  
Unblinding at the study site for any other reason,  including the scenarios described 
above, will be considered a protocol deviation.  The investigator is strongly encouraged 
3URGXFW(WDQHUFHSW
3URWRFRO1XPEHU
'DWH$XJXVW 3DJHRI
&21),'(17,$/  WRFRQWDFWWKH$PJHQ *OREDO&OLQLFDO 7ULDO0DQDJHUEHIRUHXQEOLQGLQJDQ\VXEMHFWÂ¶V
WUHDWPHQWDVVLJQPHQW,IQRWSRVVLEOHWKHLQYHVWLJDWRUPXVWL QIRUP$PJHQZLWKLQ
ZRUNLQJGD\DIWHUWKHHYHQW
 75($70(17352&('85(6
 &ODVVLILFDWLRQRI3URGXFWVDQGRU0HGLFDO'HYLFHV
7KH$PJHQ,QYHVWLJDWLRQDO3URGXFWXVHGLQWKLVVWXG\LQFOXGHV HWDQHUFHSWRUSODFHER
IRUHWDQHUFHSW
7KHQRQ$PJHQ,QYHVWLJDWLRQDOSURGXFWXVHGLQWKLVVWXG\LQFOXG HVPHWKRWUH[DWHRU
SODFHERIRUPHWKRWUH[DWH
7KHQRQ$PJHQQRQLQYHVWLJDWLRQDOSURGXFWXVHGLQWKLVVWXG\LQ FOXGHVIROLFDFLG
7KH,3,0DGRFXPHQWH[WHUQDOWRWKLVSURWRFROFRQWDLQVGHWDLO HGLQIRUPDWLRQUHJDUGLQJ
WKHVWRUDJHSUHSDUDWLRQDQGDGPLQLVWUDWLRQRIHWDQHUFHSWPHW KRWUH[DWHDQGIROLFDFLG
 ,QYHVWLJDWLRQDO3URGXFW
 $PJHQ,QYHVWLJDWLRQDO3URGXFW(WDQHUFHSW
(WDQHUFHSWZLOOEHPDQXIDFWXUHGDQGSDFNDJHGE\$PJHQ,QFDQG GLVWULEXWHGXVLQJ
$PJHQFOLQLFDOVWXG\GUXJGLVWULEXWLRQSURFHGXUHV(WDQHUFHSW ZLOOEHVXSSOLHGLQD
VLQJOHXVHSUHILOOHGP/V\ULQJHDVDVWHULOHSUHVHUYDWLYHIU HHVROXWLRQIRUVXEFXWDQHRXV
LQMHFWLRQ7KHVROXWLRQRIHWDQHUFHSWLVFOHDUDQGFRORUOHVV DQGLVIRUPXODWHGDW
S+ (DFKVLQJOHXVHSUHILOOHGV\ULQJH3)6FRQWDLQVP/RI PJPO
HWDQHUFHSWLQDIRUPXODWLRQFRQVLVWLQJRI P0 VRGLXPFKORULGH P0VRGLXP
SKRVSKDWH P0/DUJLQLQH+&/DQG VXFURVH(WDQHUFHSWZLOOE HSURYLGHGZLWK
V\ULQJHVWRDSDFN3ODFHERZLOOEHSUHVHQWHGLQLGHQWLFDOFR QWDLQHUVDQG
VWRUHGSDFNDJHGWKHVDPHDVHWDQHUFHSW 
 'RVDJH$GPLQLVWUDWLRQDQG6FKHGXOH
(WDQHUFHSWGRVLQJLQWKHVWXG\ZLOOIROORZWKHUHFRPPHQGHGODEH OGRVLQJIRUVXEMHFWV
ZLWK3V$VXEFXWDQHRXVLQMHFWLRQPJRQFHZHHNO\7KHWUHD WPHQWSHULRGRIWKLV
VWXG\LVZHHNV(WDQHUFHSWZLOOEHSURYLGHGDVDPJ3)6 P/RIDPJP/
VROXWLRQRIHWDQHUFHSW(DFKGRVHRILQYHVWLJDWLRQDOSURGXFW ZLOOFRQVLVWRIWKHFRPSOHWH
FRQWHQWVRIV\ULQJH7KHLQMHFWLRQVLWHVKRXOGEHURWDWHGZL WKHDFKGRVH6XEMHFWVZLOO
UHFHLYHGRVHRIHWDQHUFHSWSHUZHHNVFKHGXOHGDSSUR[LPDWHO\ GD\VDSDUWIRU
ZHHNV7KURXJKRXWWKHHQWLUHWULDODGPLQLVWUDWLRQRIHWDQH UFHSWVKRXOGRFFXURQWKH
VFKHGXOHGGRVHGD\KRZHYHULIXQDYRLGDEOHLWPD\EHJLYHQHD UOLHURUODWHUDVORQJDV
WKHGRVHLVQRWZLWKLQGD\VRIWKHQH[WVFKHGXOHGGRVH,IW KHGRVLQJZLQGRZLVCCI
CCI CC
ICCI CCI
Product:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075728] be 
reported on the electronic case report form (eCRF).  Subsequent doses of investigational product should resume on the original schedule.  If etanercept is to be 
taken the day of a study visit, it must be taken after the study visit has occurred (ie, at 
the subjectâ€™s location on the scheduled dose day). 
Injections of etanercept will be administered by [CONTACT_28246] a caregiver.  The individual 
administering the dose must demonstrate to the site staff that he or she is competent to 
correctly administer the subcutaneous doses.  The first dose of etanercept must be 
administered at the study site.  All subsequent doses will be administered at the subjectâ€™s location on the scheduled dose day.  Supplies of etanercept will be dispensed to subjects for administration at home.  The site will instruct the subject  in appropriate handling and storage of used and unused syringes and documentation of dosing in the 
subject diary.  The start date, quantity administered and box number of investigational 
product are to be recorded in each subjectâ€™s eCRF.  Please refer to the Investigatorâ€™s Brochure for the most recent safety information.  A link to the [LOCATION_002] Prescribing Information can be found in the Investigatorâ€™s Brochure. 
6.2.[ADDRESS_1075729]:  Methotrexate 
Non-[COMPANY_010] investigational product methotrexate  will also be used in this study.  
Methotrexate will be distributed using [COMPANY_010] clinical trial drug distribution procedures.  
Methotrexate will be supplied as 2.[ADDRESS_1075730](s) are provided in the IPIM. 
[IP_ADDRESS] Dosage, Administration, and Schedule 
Methotrexate dosing will be initiated at 10 mg weekly and will be titrated up to a final 
dose of 20 mg weekly over a 4-week period.  The treatment period for this study is 48 weeks.  Methotrexate will be provided as 2.5 mg capsules, or as placebo capsules, and will be taken once weekly by [CONTACT_782270].  Capsules should be swallowed 
whole.  Subjects will receive 1 dose of methotrexate or placebo per week (scheduled 
approximately 7 days apart) for 48 weeks.  Throughout the entire trial, administration of 
methotrexate or matching placebo should occur on the scheduled dose day; however, if unavoidable, it may be given earlier or later as long as the dose is not within [ADDRESS_1075731]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075732] be reported on the eCRF .  Double or extra doses should not be taken.  The 
start date, quantity administered, and bottle/package number of methotrexate is to be 
recorded on the subjectâ€™s diary and entered into the eCRF.  
[IP_ADDRESS] Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation 
Methotrexate (or placebo for methotrexate) will be initiated at a dosage of 10 mg weekly 
at week 0 (day 1) .  The dose will be increased by 2.5 mg weekly up to 20 mg over a 
4 week period.  In cases of typi[INVESTIGATOR_782246] (eg, increased aspartate 
transaminase or alanine transaminase, or gastrointestinal adverse effects, sever e 
stomatitis ), the methotrexate dose may be reduced up to [ADDRESS_1075733]â€™s eCRF. 
6.[ADDRESS_1075734]:  Folic Acid 
Folic acid will be sourced by [CONTACT_779].  Additional details regarding the product are 
provided in the IPIM.  
6.3.[ADDRESS_1075735] of care.  The dose of folic acid may be 
adjusted OR folinic acid  (leucovorin)  can be added not to exceed 5 mg per week  in 
response to methotrexate related toxicity. 
6.4 Hepatotoxicity Stoppi[INVESTIGATOR_53359], Reporting, and 
Monitoring  
A [LOCATION_002] Food and Drug Administration Guidance exists for drug-induced liver 
injury (DILI) (Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009) .  This guidance is general for all investigational products, and its 
recommendations can be found in Appendix A. 
6.4.1 Hepatotoxicity Stoppi[INVESTIGATOR_21866] (ie, alkaline phosphatase [ALP], AST, 
ALT, and total bilirubin [TBL]) and/or signs/symptoms of hepatitis (as described below) may meet the criteria for withholding of [COMPANY_010] investigational product or other protocol -required therapi[INVESTIGATOR_83318]- Induced Liver 
Injury:  Premarketi ng Clinical Evaluation, July 2009.  Criteria for permanent or 
conditional withholding of investigational product in the event that a subject develops signs or symptoms of hepatitis during a clinical trial is provided in Appendix A.  Criteria 
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075736] and other protocol required therapi[INVESTIGATOR_177132]  A. 
6.4.2 Hepatotoxicity Reporting and Monitoring 
Subjects with abnormal hepatic laboratory values (eg, ALP, AST, ALT, TBL , or 
signs/symptoms of hepatitis) may require follow- up, depending upon the clinical 
circumstances discussed below (as specified in the Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical Evaluation, July 2009). 
6.4.[ADDRESS_1075737] TBL > [ADDRESS_1075738] or ALT >  [ADDRESS_1075739] the event 
submitted to [COMPANY_010] as a serious adverse event within 24 hours following the investigatorâ€™s knowledge of the event (ie, before additional etiologic investigations have been concluded).  Additional Clinical Assessments and Observation in subjects who 
experience AST or ALT elevations  > [ADDRESS_1075740]â€™s baseline levels.  Assessments to be performed during this 
period are outlined in Appendix  A. 
6.[ADDRESS_1075741]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075742] who meets the criteria for inadequate 
response and begins rescue treatment as described in Section 3.1.2.  
6.6 Medical Devices 
Medical devices (eg, alcohol prep pads), that are commercially available are not usually provided or reimbursed by [CONTACT_11337] (except, for example, if required by [CONTACT_1295]).  The investigator will be responsible for obtaining supplies of these devi ces. 
6.[ADDRESS_1075743](s) or device(s). 
Any product complaint(s)  associated with an investigational product(s) or 
non-investigational product(s) or device(s) supplied by [CONTACT_147232].  
6.8 Excluded Treatments and/or Procedures During Study Period 
Proscribed medications during this study include the following: 
â€¢ Abatacept 
â€¢ Anakinra 
â€¢ Any other investigational agents or commercially available biologics  
â€¢ Otezla (apremilast) 
â€¢ Azathioprine  
â€¢ Sulfas alazine 
â€¢ Leflunomide 
â€¢ Cyclosporine 
â€¢ Cytotoxic agents including chlorambucil, cyclophosphamide, nitrogen mustard, or 
other alkylating agents 
â€¢ Gold  
â€¢ Intraarticular, intramuscular, or intravenous corticosteroids, including adrenocorticotropic hormone  
â€¢ Intraarticular hyaluronic acid injec tions  
â€¢ Mycophenolate mofetil  
â€¢ Systemic tacrolimus  
â€¢ Live vaccines  
Product:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075744] agree to practice true sexual abstinence 
(refrain from heterosexual intercourse) or use a highly effective method of contraception 
during treatment and for an additional [ADDRESS_1075745] dose of protocol required therapi[INVESTIGATOR_014].  
Contraceptive methods that achieve a failure rate less of less than 1
% per year when 
used consistently and correctly are considered highly effective and may include:  hormonal (combined estrogen and progestogen or progestogen only), contraception 
associated with inhibition of ovulation (oral , injectable, implantable, intravaginal, or 
transdermal route) , intrauterine device, i ntrauterine hormonal -releasing system , bilateral 
tubal occlusion, v asectomized partner (provided that partner is the sole sexual partner of 
the female participant and the vasectomized partner has received medical assessment of the surgical success) , true sexual abstinence when this is in line with the preferred 
and usual lifestyle of the subject.  The reliability of sexual abstinence must be evaluated 
by [CONTACT_471905]. 
If a female subject is suspected of being pregnant, the protocol -required therapi[INVESTIGATOR_782247]. Females not of child-bearing potential are defined as:  a ny female who has had a 
hysterectomy, OR bilateral salpi[INVESTIGATOR_1656], OR bilateral oophorectomy, OR are 
postmenopausal.  Postmenopausal women are those who have had no spontaneous menses for at least [ADDRESS_1075746] agree to practice 
true sexual abstinence (refrain from heterosexual intercourse) or use a condom with 
spermicide (if spermicide is commercially available) during treatment and for an additional [ADDRESS_1075747]:  Etanercept  
Protocol Nu mber:  20130207  
Date:  [ADDRESS_1075748] 2016  Page 31 of 76 
CONFIDENTIAL    The female partner should also consider using an acceptable method of effective 
contraction such as:  hormonal, intrauterine device, i ntrauterine hormonal -releasing 
system , female barrier method (diaphragm, cervical cap, contraceptive sponge; a female 
condom is not an option because there is a risk of tearing when both partners use a condom). 
Male subjects with a pregnant partner must practice sexual abstinence or wear a 
condom to prevent exposure of the unborn child to methotrexate through semen. 
Unacceptable methods of b irth c ontrol for male and female subjects include b irth control 
methods that are considered unacceptable in clinical trials and include:  p eriodic 
abstinence (calendar, symptothermal, postovulation methods), w ithdrawal (coitus 
interruptus), spermicides only, and l actational amenorrhoea method. 
7. STUDY PROCEDURES  
Screening assessments and study procedures outlined in this section and in Table [ADDRESS_1075749]â€™s medication for the purpose of participation in this study. 
All on study visits should be scheduled from day 1 (date of the firs t dose of 
investigational product) on the study.  It is very important to attempt to perform study 
procedures and obtain samples at the precise timepoints stipulated below.  When it is 
not possible to perform the study visit at the exact timepoint, the visit may be performed 
within the acceptable visit window as defined in the visit-specific section below. 
With the exception of the screening and re-screen visits , and the radiographic 
assessments , all study procedures for a visit should be completed on the same day.  
Radiographs may be done within 
Â± [ADDRESS_1075750]:  Etanercept  
Protocol Number:  20130207  
Date:  [ADDRESS_1075751] 2016  Page 32 of 76 
CONFIDENTIAL  Table 1 .  Schedule of Assessments 
30-day 
Screening  Treatment  Period  Disease Assessment 
(DA)  30-day 
Follow -Up 
Weeks  0 (day 1)  4 8 12 16 24 36 48/ET DA Visite DA Follow -upe Safety (EOS)g
GENERAL & SAFETY ASSESSMENTS  
Informed consent  X 
Randomization via IXRS X 
Medical/Medication history  X 
Concomitant medications X X X  X X X X X X X 
Adverse events  X X X X X X X X X X 
Serious adverse events  X X X X X X X X X X X X 
Physical examinationa X X X X X X X X 
Vital signs  X X X X X X X X X X X 
Weight  X X X X X 
Height  X 
LABORATORY ASSESSMENTS  
Pregnancy test (serum)bX 
Pregnancy test (urine)b,cX X X X X  
Tuberculosis testingd X 
Hematology and chemistry profile X X X X X X X X X 
Hepatitis B surface antigen & core antibody ; Hepatitis C virus 
antibodyiX 
High Sensitivity C-reactive Protein X X X  X X X X X X X 
Urinalysis  X X 
Biomarker blood sample  X X X X 
INVESTIGATIONAL PRODUCT DISPENSI NG 
Etanercept/placebo for etanercept dispensation  X X X X X X Xf X 
Methotrexate/placebo for methotrexate dispensation  X X X X X X Xf X 
Folic Acidh X X X X 
SUBJECT DIARY DISPENSING  
Dispense subject diary  X X X X X X X 
Review subject diary X X X X X X X X X 
DISEASE ASSESSMENTS  
Swollen and Tender joint count  X X X X X X X X X X X 
Physician Global Assessment of Disease Activity (VAS 0 to 100)  X X X X X X X X X X 
Leeds Dactylitis  Index  X X X X X X X X 
Spondyloarthritis Research Consortium of Canada  (SPARCC) 
Enthesitis  Index  X X X X X X X X 
Modified Nail Psoriasis Severity Index ( NAPSI ) X X X X X X 
Static Physician Global Asses sment of Psoriasis  X X X X X X X X 
Body Surf ace Area  X X X X X X X X 
Radiographs (hands, feet) X X X 
Page [ADDRESS_1075752]:  Etanercept  
Protocol Number:  20130207  
Date:  [ADDRESS_1075753] 2016  Page 33 of 76 
CONFIDENTIAL    Table 1 .  Schedule of Assessments 
 30-day 
Screening  Treatment Period  Disease Assessment 
(DA)  30-day 
Follow -Up 
Weeks  0 (day 1)  4 8 12 16 24 36 48/ET DA Visite DA Follow -upe Safety (EOS)g 
PATIENT REPORTED OUTCOMES              
Patient global assessment of pain (VAS 0 to 100)   X X X X X X X X X X  
Patient global assessment of disease activity (VAS 0 to 100)  X X X X X X X X X X  
Disability Index of the Health Assessment Questionnaire  
(HAQ -DI)  X X X X X X X X X X  
Medical Outcomes Short Form-36 Questionnaire ( SF-36)  X   X  X X X    
Page 2 of 2  
ET: early termination; DA:  Disease Assessment; EOS:  end of study ; HBV :  hepatitis B virus;  IXRS :  Interactive voice response system; PCR:  polymerase chain 
reaction;  VAS:  visual analog scale  
aScreening physical exam will be a full exam; subsequent exams per standard of care to monitor for any changes  
bFor all women, unless  at least [ADDRESS_1075754]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075755] is positive for 
hepatitis B core antibody, the confirmatory reflex testing will be performed using 
hepatitis B virus (HBV ) DNA polymerase chain reaction ( PCR).  Subjects  who screen 
fail may be eligible to re -screen two additional times per Section 7.2.2.  
7.2.[ADDRESS_1075756] be repeated.  If the re-screening occurs within 30 days after the original signing of the informed consent, only those criteria that were originally not met would be required to be 
repeated.  Subjects who screen fail for not meeting inclusion criterion 106 or  111 are not 
permitted to re-screen.  
7.2.3 Baseline Visit (Day 1)  
Subjects meeting all eligibility criteria will be randomized by [CONTACT_782271] [ADDRESS_1075757]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075758] for self -administration per  Table 1 . 
7.2.4 Treatment  
Visits will occur per the Schedule of Assessments (Table 1 ) during the treatment period 
from day 1 until week 48.  On-study visits may be completed within Â± 7 days of the target 
visit date.  The procedures completed during the 48-week treatment period are those 
listed in the Schedule of Assessments ( Table 1 ).  Administration of investigational 
product is to be administered after all other study procedures, as applicable, during each visit that is required.  
7.2.[ADDRESS_1075759] meets the criteria for inadequate response as defined in 
Section 3.1.2,  he/she will initi ate rescue treatment with etanercept (50 mg QW) plus  
methotrexate (titrated up to 20 mg QW).  Sites will register the requirement for rescue in 
the IX RS for assignment of rescue therapy.  Refer to the IPIM for additional details.  
Subjects will continue to receive etanercept plus methotrexate for the remaining study 
visits per  Table 1 .  The procedures completed during the Disease Assessment visit are 
listed in the Schedu le of Assessments ( Table 1 ).  Subjects who initiate rescue treatment 
must complete a Disease Assessment Follow -up visit 4 to 5 weeks later to complete all 
the procedures listed in the Schedule of Assessments ( Table 1 ). 
7.2.[ADDRESS_1075760] End of Treatment/Early Termination 
Subjects will complete an end of treatment visit at week 48 within a window of 
Â± 7 days 
of the target visit date (see Table 1 ).  Subjects ending the study prior to week  48 will be 
asked to complete an Early Termination visit.  
7.2.7 Safety Follow -up/End of Study  
Approximately 30 days, within a window of + [ADDRESS_1075761] any serious adverse events (refer to Section 9). 
7.[ADDRESS_1075762]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075763] sign and personally date the 
IEC/IRB approved informed consent before any study -specific procedures are 
performed. See Section 11.[ADDRESS_1075764] â€™s full PsA history and other significant medical history should be recorded 
starting at the time of the original diagnosis.  Other relevant medical and surgical history 
that started within [ADDRESS_1075765]â€™s concurrent medical 
conditions  will be recorded. Record all findings on the medical history eCRF. 
7.3.[ADDRESS_1075766]â€™s full history of psoriasis and PsA medications starting at the time of 
diagnosis and up to screening will be recorded on the eCRF.  This information will 
include the subjectâ€™s non-biologic DMARDs, NSAIDs , corticosteroids , biologics , and 
inves tigational medication history.  For PsA medications, the following information will be 
recorded in the eCRF:  medication name, indication, dose, unit, route, frequency, and 
start and stop dates.  For all other medications, only the medication name, indication, and start and stop dates will be recorded in the eCRF.  
7.3.[ADDRESS_1075767] of care. Physical examination findings at screening should be recorded on the appropriate eCRF (eg, medical history).  
The physical examination at subsequent study visits will consist of an interim 
examination to monitor for any changes from the screening physical examination.  Any clinically significant changes in physical examination per the Principal Investigatorâ€™s opi[INVESTIGATOR_177133]. 
7.3.6 Physical Measurement  
Height in inches /centimeters  and weight in pounds /kilograms  should be measured 
without shoes . 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075768] be performed:  systolic and diastolic blood pressur e, 
heart rate, respi[INVESTIGATOR_697], and temperature.  Subject must be in a supi[INVESTIGATOR_33197] a 
rested and calm state for at least [ADDRESS_1075769] their assessments done by 
[CONTACT_75600], if possible.  If necessary, study visits may be 
rescheduled within the allowed window period per visit in order to accommodate when 
the same assessor will be available.  
[IP_ADDRESS] Swollen/Tender Joint Counts 
All joint assessments will be performed by [CONTACT_782272] â€™s Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis  (GRAPPA) training module and must be identified on the delegation of 
authority for this responsibility .  The user ID  of the joint assessor will be recorded at each 
assessment .  The score for each joint will be recorded directly into the el ectronic 
PRO  tablet which will serve as the source documentation and will not be transposed to 
the eCRF .  Joints that have been replaced are considered inevaluable. 
Swollen Joint Count Assessments â€“ A total of 66 joints will be scored for presence or 
absence of swelling.  
Tender Joint Count Assessments â€“ A total of 68 joints will be scored for presence or 
absence of tenderness.  
[IP_ADDRESS] Leeds Dactylitis Index  
Assessment will be performed by [CONTACT_782273].  The assessor 
will be trained by [CONTACT_782274]. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075770] 2016  Page 38 of 76 
CONFIDENTIAL    The assessor will assess all fingers and toes for tenderness in the area between the 
joints and will score each on a scale of 0 to 3 where 0 = not tender; 1 = tender; 
2 = tender and wince; 3 = tender and withdraw.  Using a Leeds dactylometer , the 
circumference of only the tender digits and their contralateral counterpart will be 
measured and reported on the eCRF . 
[IP_ADDRESS] Spondyloarthritis Research Consortium of Canada Enthesitis Index 
Assessment will be performed by [CONTACT_782273].  The assessor 
will be trained by [CONTACT_782275] ( SPARCC) enthesitis assessment.   The SPARCC 
enthesitis index  assesses enthesitis at 18 sites with a resultant score of 0 to 16.  
Tenderness at each site is assessed as 0 = non-tender or 1 = tender. Entheses 
assessed are left and right medial and lateral epi[INVESTIGATOR_100758], supraspi[INVESTIGATOR_782248], greater trochanter, quadriceps insertion into superior 
border of patella, patellar ligament insertion into inferior pole of patella, tibial tubercle, 
Achilles tendon insertion into calcaneum  and bilateral plantar fascia inserti on into the 
calcaneum .  Higher count represents greater enthesitis burden.  Tenderness at the 
inferior pole of patella and/or tibial tubercle will be scored as a maximum score of 1. 
[IP_ADDRESS] Radiographs 
Radiographs  of bilateral hands and feet will be taken in the required views:  
posterior/anterior for the hands and anterior/posterior for the feet.  Radiographs will be 
done locally and read centrally. 
The central imaging vendor will measure using the van der Heijde mTSS  method for 
PsA.  This method is based on the Sharp-van der Heijde method for assessing erosions 
and joint space narrowing of the hands and feet in RA  and is adapted for evaluation of 
PsA by [CONTACT_782276], ankylosis, gross osteolysis , 
and pencil in cup phenomena.  Erosions are scored from [ADDRESS_1075771]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075772] 2016  Page 39 of 76 
CONFIDENTIAL    7.3.9 Psoriasis Disease Assessments 
[IP_ADDRESS] Static Physician Global Assessment of Psoriasis 
The assessor who conducts the tender and swollen joint counts will be trained and 
certified by [CONTACT_782277] G lobal Assessment 
of Psoriasis (sPGA).  The sPGA is designed to evaluate the physicianâ€™s global 
assessment of the subjectâ€™s psoriasis based on severity of induration, scaling, and 
erythema.  The sPGA is assessed on a scale of 0 (clear) to 5 (severe) . 
[IP_ADDRESS] Body Surface Are a Involvement 
The assessor who conducts the tender and swollen joint counts will be trained and 
certified by [CONTACT_782278] e to perform the assessment for involved b ody 
surface area (BSA).  BSA is a numerical score (0 to 100) used to measure the proportion 
of the subjectâ€™s total BSA involvement with psoriasis.  
[IP_ADDRESS] Modified Nail Psoriasis Severity Index 
The assessor who conducts the tender and swollen joint counts will be trained and 
certified by [CONTACT_782279].  The modified NAPSI 
scale is an objective, numeric, and reproducible grading system for nail psoriasis that 
incorporates the many different features of nail psoriasis.  For assessments in this study (including selection of the target nail), a nail is graded on the following 8 clinical features and the modified NAPSI score results. 
â€¢ pi[INVESTIGATOR_22940] (scores 0-3, depending on the number of pi[INVESTIGATOR_10022])  
â€¢ nail plate crumbling (scores 0-3, depending on % of nail involvement)  
â€¢ onycholysis  and oil drop discoloration considered together  (scores 0 -3, depending on 
% of nail involvement)  
â€¢ leukonychia (0 or 1 â€“ absent or present)  
â€¢ red spots in lunula (0 or 1 â€“ absent or present)  
â€¢ nail bed hyperkeratosis (0 or 1 â€“ absent or present)  
â€¢ splinter hemorrhages (0 or 1 â€“ absent or present)  
In randomized subjects with nails involved with psoriasis, each finger nail will be scored 
at baseline to determine the wors t nail (ie, the nail with the highest modified NAPSI 
score ); this  nail will be followed for the remainder of the study.  If multiple nails have the 
same worst score, only [ADDRESS_1075773]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075774] 2016  Page 40 of 76 
CONFIDENTIAL    [IP_ADDRESS] Phy sician Global Assessment of D isease Activity  
This assessment will be completed by [CONTACT_782280] (PI) for the study  by [CONTACT_37142] a visual analog scale (VAS). The VAS is 
100 mm in length with â€œ0â€ and â€œNo Activity  at Allâ€ on the left end of the line and â€œ100 â€ and 
â€œWorst Activity Imaginableâ€ at the right end of the line.  The subject and joint assessor or 
PI [INVESTIGATOR_782249]. 
7.3.[ADDRESS_1075775] (before other study procedures and 
administration of study medication) at each visit where they are required. 
[IP_ADDRESS] Patient Global Assessment of Joint Pain 
The severity of the subjectâ€™s joint pain will be assessed by [CONTACT_37142] a VAS. The 
horizontal line is 100 mm in length with â€œ0â€ and â€œno pain at all â€ on the left end of the line 
and â€œ100â€ and â€œworst pain imaginableâ€ on the right end of the line.  This questionnaire 
should take approximately 1 minute to complete. 
[IP_ADDRESS] Patie nt Global Assessment of Disease Activity 
The subjectâ€™s global assessment of their arthritis disease activity will be assessed by 
[CONTACT_37142] a VAS.  The horizontal line is 100 mm in length with â€œ0â€ and â€œNo arthritis 
activity at allâ€ on the left end of the line and â€œ100 â€ and â€œWorst arthritis a ctivity imaginableâ€ 
on the right end of the line.  The subject and physician must complete the global 
assessments independently from each other.  This questionnaire should take 
approximately 1 minute to complete. 
[IP_ADDRESS] Disability Index of the Health Assessment Questionnaire 
The Disability Index of the Health Assessment Questionnaire ( HAQ -DI) will be utilized to 
assess the subjectâ€™s physical function or disability according to the subject.  The HAQ -DI 
asks about the degree of difficulty a person has in accomplishing tasks in 8 functional 
areas (dressing, arising, eating, walking, hygiene, reaching, grippi[INVESTIGATOR_007], and errands and 
chores).  Responses in each functional area are scored from [ADDRESS_1075776]. This questionnaire should take approximately 5 minutes to complete. 
[IP_ADDRESS] Medical Outcomes Short Form -36 Questionnaire 
The Medical Outcomes Short Form- 36 Questionnaire ( SF-36) is a 36-item instrument 
that measures general health status.   It includes [ADDRESS_1075777]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075778] 2016  Page 41 of 76 
CONFIDENTIAL    assess 1 of the following 8 health concepts:  1)  limitations in physical activities because 
of health problems; 2) limitations in social activities because of physical or emotional 
problems; 3) limitations in usual role activities because of physical health problems; 
4) bodily pain; 5) general mental health (psychological distress and well -being); 
6) limitations in usual  role activities because of emotional problems; 7) vitality (energy 
and fatigue); and 8) general health perceptions .  The SF-[ADDRESS_1075779]â€™s 
perception of health status over the previous month and takes about 15 minutes to complete.  
7.4 Laboratory Assessments 
All screening and on-study laboratory samples will be processed and sent to the central 
laboratory with the exception of urine pregnancy, [COMPANY_003], and Quantiferon (may be done by [CONTACT_177152]).  The central laboratory will be responsible for all screening 
and on-study serum chemistry, hematology, serum pregnancy, urinalysis, high sensitivity C-reactive protein, and any other laboratory tests required.  U rine pregnancy and [COMPANY_003] 
testing, if applicable, will be performed locally with kits provided by [CONTACT_2237] (except [COMPANY_003]).  The results of this testing will be maintained in the source documents at 
the site.  [COMPANY_010] or designee will be responsible for biomarker development and 
pharmacogenetic assessments, and the central laboratory will ship the samples to 
[COMPANY_010] or a specialty laboratory for assay (depending on the assessment).  The central 
laboratory will provide a study manual that outlines handling, labeling, and shippi[INVESTIGATOR_782250].  All blood samples will be obtained by [CONTACT_782281].  The date and time of sample collection will be 
recorded in the source documents at the site.  Specific analytes for serum chemistry, 
hematology, C-reactive protein, urinalysis, and other testing to be conducted on blood 
and urine samples are listed below ( Table 2 ). 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075780] (SGOT)  
ALT (SGPT)  Urinalysis  
Specific gravity  
pH 
Blood  
Protein  
Glucose  
Bilirubin  
Microscopic (Reflex 
testing if > trace ) 
â€¢Bands/stabsHematology  
WBC  
Absolute neutrophil 
count  
RBC  
Hemoglobin  
Hematocrit  
MCV  
MCH  
MCHC  
RDW 
Reticulocytes  
Platelets  
WBC Differential  
â€¢Eosinophils
â€¢Basophils
â€¢Lymphocytes
â€¢Neutrophils
â€¢Monocytes
a For all women, unless at least [ADDRESS_1075781] at screening per Section 4.1.1.  
[IP_ADDRESS] [COMPANY_003] 
The [COMPANY_003] test must be read by a trained healthcare professional [ADDRESS_1075782] is placed. 
[IP_ADDRESS] Quantiferon 
If a subject does not receive a [COMPANY_003] test, then a Quantiferon test must be performed per 
Section 4.1.1.  Please refer to the central laboratory manual for instructions on sample 
collection, processing, and shippi[INVESTIGATOR_26172] (if applicable). 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075783] be held; if pregnancy is confirmed, then investigational 
product must be discontinued. 
7.5 Biomarker Development  
Biomarkers are objectively measured and evaluated indicators of normal biologic 
processes, pathogenic pr ocesses, or pharmacologic responses to a therapeutic 
intervention.  Biomarker development can be useful in developi[INVESTIGATOR_53391], guide therapy, and/or predict disease severity. 
[COMPANY_010] may attempt to develop test(s) designed to identify subjects most likely to 
respond positively or negatively to etanercept and/or methotrexate.  Biomarker development may be pursued by [CONTACT_782282], such as proteomic methods or ribonucleic acid transcript profiling.  A cell pel let from the blood 
plasma tube may be utilized to assess the impact of etanercept and/or methotrexate on 
circulating immune cells via deoxyribonucleic acid (DNA) methylation analysis, a pharmacodynamic assessment of methylation patterns of relevant genes.  The DNA 
extracted will not be used for optional pharmacogenetic analyses unless the subject signs the additional consent. 
7.[ADDRESS_1075784] consents to the optional pharmacogenetic portion of this study, DNA 
analyses may be performed.  These optional pharmacogenetic analyses focus on 
inherited genetic variations to evaluate their possible correlation to the disease and/or 
responsiveness to the therapi[INVESTIGATOR_44809].  The goals of the optional studies 
include the use of genetic markers to help in the investigation of PsA and/or to identify 
subjects who may have positive or negative response to [COMPANY_010] and non -[COMPANY_010] 
investigational product. No additional samples are collected for this part of the study.  For subjects who consent to this/these analysis/analyses, DNA may be extracted. 
7.7 Sample Storage and Destruction 
Any blood sample collected according to the Schedule of Assessments ( Table 1 ) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to 
minimize risks to study subjects.  This includes testing to ensure analytical methods 
produce reliable and valid data throughout the course of the study.  This can also 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075785], [COMPANY_010] can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand 
inflammatory conditions,  the dose response and/or prediction of response to etanercept 
or methotrexate, and characterize aspects of the molecule (eg, mechanism of 
action/target, metabolites).  Results from this analysis are to be documented and maintained, but are not necessarily reported as part of this study.  Samples can be 
retained for up to [ADDRESS_1075786]â€™s medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in  the informed consent.  
The subject retains the right to request that the sample material be destroyed by [CONTACT_782283].  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining 
blood samples and any other components from the cells can be located and destroyed.  
Samples will be destroyed once all protocol -defined procedures are completed.  
However, information collected from samples prior to the request for destruction, will be retained by [CONTACT_11337].  
The sponsor
 is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the request of the subject through the investigator, at the end of the storage period, or as appropriate (eg, the scientific rationale for experimentation with a certain sample type no longer justifies keepi[INVESTIGATOR_21878]).  If a commercial product is developed from this 
research project, the sponsor owns the commercial product.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075787] sâ€™ Decision to Withdraw  
Subjects have the right to withdraw from the study at any time and for any reason without prejudice to their  future medical care by [CONTACT_8018].  
Subjects can decline to continue receiving investigational product and/or other 
protocol -required therapi[INVESTIGATOR_33204].  If this occurs, the investigator is to discuss with the subject the 
appropriate processes for discontinuation from investigational product or other 
protocol -required therapi[INVESTIGATOR_33205]  (Table 1 ) and collection of data, including 
endpoints and adverse events.  The i nvestigator  must document the change to the 
Schedule of Assessments (Table 1 ) and the level of follow -up that is agreed to by [CONTACT_1560] ( eg, in person, by [CONTACT_756]/mail, through family/friends, in 
correspondence/communication with other physicians, from review of the medical records ). 
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -required therapi[INVESTIGATOR_21882] , and the subject does not wish to or is 
unable to continue further study participation.  Su bject data up to withdrawal of consent 
will be included in the analysis of the study , and where permitted, publically available 
data can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study.  The data generated may potentially  not be included in the subjectâ€™s study data, except in the case of a possibly 
related serious adverse event, where data will be collected.  
8.2 Investigator or Sponsor Decision to Withdraw  or Terminate 
Subjectsâ€™ Participation Prior to Study Completion 
The i nvestigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product and/or other protocol -required therapi[INVESTIGATOR_014], protocol procedures , or the study as a 
whole at any time prior to study completion. 
Subjects may be eligible for continued treatment with [COMPANY_010] investigational product(s) and/or other protocol -required therapi[INVESTIGATOR_21883] a separate protocol or as provided for by [CONTACT_21956]â€™s regulatory mechanism, based on parameters consistent with Section 12.1. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075788](s) or procedural 
assessments include  any of the following: 
â€¢ subject request 
â€¢ safety concern (eg, due to an adverse event, ineligibility d etermined, protocol 
deviation, non-compliance, requirement for alternative therapy, pregnancy)  
â€¢ death 
â€¢ lost to follow -up 
â€¢ decision by [CONTACT_3211]  (other than subject request, safety concern, death or lost to 
follow -up) 
â€¢ disease flare requiring treatment not allowed in the protocol (eg, c olitis, asthma)  
8.3.[ADDRESS_1075789] from the study  are: 
â€¢ decision by [CONTACT_3211]  
â€¢ withdrawal of consent from study  
â€¢ death 
â€¢ lost to follow -up 
9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING  
9.[ADDRESS_1075790]â€™s medical record.  
The definition of adverse events includes  worsening of a pre-existing medical condition.  
Worsening indicates that the pre-exist ing medical condition (eg, diabetes, migraine 
headaches, gout) has increased in severity, frequency, and/or duration, and/or has an association with a significantly worse outcome.  A pre-existing condition that has not worsened during the study or involves  an intervention such as elective cosmetic surgery 
or a medical procedure while on-study , is not considered an adverse event. 
The investigatorâ€™s clinical judgment is used to determine whether a subject is to be 
removed from treatment due to an adverse event.  In the event a subject, or subjectâ€™s legally acceptable representative requests to withdraw from protocol -required therapi[INVESTIGATOR_782251]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075791] 1 of the 
following serious criteria:  
â€¢ fatal 
â€¢ life threatening (places the subject at immediate risk of death)  
â€¢ requires in-patient hospi[INVESTIGATOR_1081] 
â€¢ results in persistent or significant disability/incapacity 
â€¢ congenital anomaly/birth defect  
â€¢ other medically important serious event  
An adverse event would meet the criterion of â€œrequires hospi[INVESTIGATOR_059]â€, if the event necessitated an admission to a health care facility (eg, overnight stay). 
If an i nvestigator considers an event to be clinically important, but it does not meet any 
of the serious criteria, the event could be classified as a serious adverse event under the 
criterion of â€œother medically important serious eventâ€.  Examples of such events could 
include allergic bronchospasm, convulsions, blood dyscrasias, DILI (see Appendix  A for 
DILI reporting criteria), or events that necessitate an emergency room visit, outpatient surgery, or urgent intervention.  
9.[ADDRESS_1075792](s) through the end of treatment period a re reported using the applicable CRF 
(eg, Adverse Event Summary).  
The investigator must assign the following adverse event attributes:  
â€¢ Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms), 
â€¢ Dates of onset and resolution (if res olved) , 
â€¢ Severity (and/or toxicity per protocol ), 
â€¢ Assessment of relatedness to investigational product(s) and 
â€¢ Action taken. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075793](s).  
This relationship is indicated by a â€œyesâ€ or â€œnoâ€ response to the question:  Is there a 
reasonable possibility that the event may have been caused by [CONTACT_7198](s)? 
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a cl inically 
significant change from the subjectâ€™s baseline values.  In general, abnormal laboratory 
findings without clinical significance (based on the investigator's judgment) are not to be 
recorded as adverse events.  However, laboratory value changes that require treatment 
or adjustment in current therapy are considered adverse events.  Where applicable, 
clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse 
event. 
The Investigator is expected to follow reported a dverse events  until stabilization or 
reversibility. 
If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the Adverse Event Summary CRF. 
9.2.[ADDRESS_1075794](s) are recorded in the subjectâ€™s medical record and are submitted to [COMPANY_010].   All 
serious adverse events must be submitted to [COMPANY_010] within 24 hours following the 
investigatorâ€™s knowledge of the event via the applicable e CRF.  
After the protocol -required reporting period defined above, the investigator does not 
need to actively monitor subjects for serious adverse events.  However, if the investigator becomes aware of a serious adverse event after this protocol -required 
reporting period, the investigator will report the event to [COMPANY_010] within 24 hours following 
the investigatorâ€™s knowledge of the event.  Serious a dverse events reported outside of 
the protocol -required reporting period will be captured within the safety database as 
clinical trial cases for the purposes of expedited reporting. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075795] 2016  Page 49 of 76 
CONFIDENTIAL    If the electronic data capture (EDC) system is unavailable to the site staff to report the 
serious adverse event, the information is to be reported to [COMPANY_010] via an eSAE 
Contingency Report Form within 24 hours of the investigatorâ€™s knowledge of the event. 
See Appendix  B for a sample of the Serious Adverse Event Worksheet/eSAE 
Contingency Report Form.  For EDC studies  where the first notification of a Serious  
Adverse Event is reported to [COMPANY_010] via the eSAE Contingency Report Form, the data 
must be entered into the EDC system when the system is again available. 
The investigator must assess whether the serious adverse event is possibly related to 
any study -mandated activity or procedure.  This relationship is indicated by a â€œyesâ€ or 
â€œnoâ€ response to the question:  â€œIs there a reasonable possibility that the event may have 
been caused by a study activity/procedure?â€ 
The investigator is expected to follow reported serious adverse events until stabilization 
or reversibility.  
New information relating to a previously reported serious adverse event must be 
submitted to [COMPANY_010].   All new information for serious adverse events must be sent to 
[COMPANY_010] within [ADDRESS_1075796] be consistent with that recorded on the applicable e CRF 
(eg, Adverse Event Summary CRF). 
If a subject is permanently withdrawn from protocol -required therapi[INVESTIGATOR_21889] a 
serious adverse event, this information must be submitted to [COMPANY_010].  
To comply with worldwide reporting regulations for serious adverse events, the treatment assignment of subjects who develop serious, unexpected, and related adverse events may be unblinded by [CONTACT_21960].  Investigators 
will receive notification of related serious adverse event reports sent to regulatory authorities in accor dance with local requirements. 
[COMPANY_010] will report serious adverse events and/or suspected unexpected serious adverse 
reactions as required to regulatory authorities, investigators/institutions, and IRBs/IECs 
in compliance with all reporting requirements according to local regulations and GCP .  
The investigator is to notify the appropriate IRB/I EC of serious adverse events occurring 
at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedures and statutes.  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075797] dose of  etanercept. 
The pregnancy should be reported to [COMPANY_010]â€™s global Pregnancy Surveillance Program  
within 24 hours of the investigatorâ€™s knowledge of the event of a pregnancy.  Report a 
pregnancy on the Pregnancy Notification Worksheet (Appendix  C).  The Pregnancy 
Surveillance Program w ill seek to follow the pregnant woman throughout her pregnancy 
and her baby [CONTACT_8622] [ADDRESS_1075798] dose of etanercept. 
Any lactation case should be reported to [COMPANY_010]â€™s global Lactation Surveillance Program 
within 24 hours  of the investigatorâ€™s knowledge of event.  Report a lactation case on the 
Lactation Notification Worksheet (Appendix  C). 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints, Analysis Sets, and Covariates 
10.1.1 Study Endpoints 
[IP_ADDRESS] Primary Endpoint  
â€¢ ACR 20 response at week 24  
[IP_ADDRESS] Key Secondary Endpoint  
â€¢ MDA response at week 24 
[IP_ADDRESS] Other Secondary Endpoints 
â€¢ Modified NAPSI score and change from baseline at week 24  
â€¢ Leeds dactylitis  score  and change from baseline at week 24  
â€¢ SPARCC enthesitis score and change from baseline at week 24  
â€¢ ACR 20 response at all other measured timepoints  
â€¢ MDA response at all other measured timepoints  
â€¢ Psoriatic Arthritis Disease Activity Score (PASDAS) at all measured timepoints  
â€¢ ACR 50, ACR 70, and components of ACR at all measured timepoints  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075799] 2016  Page 51 of 76 
CONFIDENTIAL    â€¢ Simplified Disease Activity Index (S DAI) and change from baseline at all measured 
timepoints  
â€¢ Clinical Disease Activity Index (C DAI) and change from baseline at all measured 
timepoints  
â€¢ Disease activity score (28 joint) using the C -reactive protein formula (DAS 28-CRP ) 
and change from baseline at all measured timepoints  
â€¢ HAQ -DI score and change from baseline at week 24 
â€¢ SF-3 6 score and change from baseline at week 24 
For subjects with involved BSA â‰¥ 3% at baseline:  
â€¢ sPGA at week 24  
â€¢ BSA at week 24 
[IP_ADDRESS] Safety Endpoints 
â€¢ Adverse events  
â€¢ Serious adverse events  
â€¢ Laboratory parameters and vital signs  
[IP_ADDRESS] Exploratory Endpoints 
â€¢ Change from baseline in van der Heijde mTSS at week 24 and week 48 
â€¢ Non-progression in van der Heijde mTSS defined as change â‰¤ 0 from baseline at 
week 24 and week 48 
â€¢ Modified NAPSI score and change from baseline at all other measured timepoints  
â€¢ Leeds dactylitis  score  and change from baseline at all other measured timepoints  
â€¢ SPARCC enthesitis  score  and change from baseline at all other measured 
timepoints  
â€¢ HAQ -DI and change from baseline at all other measured timepoints  
â€¢ SF-36v2 and change from baseline at all other measured timepoints  
For subjects with involved body surface area â‰¥ 3% at baseline: 
â€¢ sPGA  at all other measured timepoi nts  
â€¢ BSA at all other measured timepoints  
10.1.2 Analysis Sets 
[IP_ADDRESS] Full Analysis Set  
The full analysis set will include all randomized subjects.  Subjects will be analyzed 
according to their randomized treatment group.  Demographics, baseline disease characteristics, and non- psoriasis efficacy analyses will be based on the full analysis set.  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075800] 2016  Page 52 of 76 
CONFIDENTIAL    [IP_ADDRESS] Psoriasis Efficacy Analysis Set  
The psoriasis efficacy analysis set will consist of all randomized subjects with baseline 
BSA â‰¥ 3%.  Analyses of psoriasis efficacy endpoints (eg, sPGA, BSA) will be based on the psoriasis efficacy analysis set.  
[IP_ADDRESS] Safety Analysis Set  
The safety analysis set will consist of all randomized subjects who receive at least one 
dose of investigational product.  Subjects will be analyzed according to the actual 
treatment received.  Analyses of safety endpoints will be based on the safety analysis set. 
10.1.3 Covariates and Subgroups 
The following covariates will be considered to assess their influence on the primary and key secondary endpoints: 
â€¢ Age (
â‰¤ 65, >  65) 
â€¢ Sex (male, female)  
â€¢ Race  (Caucasian, Non- Caucasian)  
â€¢ Ethnicity  (Hispanic or Latino vs Non-Hispanic or Latino)  
â€¢ Baseline body mass index (BMI ) (â‰¤ 30, > 30) 
â€¢ Baseline weight ( â‰¤ 100 kg, >  100 kg) 
â€¢ Baseline BSA ( â‰¤ 3%, > 3%) 
â€¢ Prior use of non-biologic DMARD (yes, no)  
â€¢ Disease duration ( â‰¤ median, > median) 
Subgroup analyses, which would be considered exploratory, may be performed if an 
examination of the above covariates suggests that any treatment difference for the 
prima ry and secondary endpoints depends on any baseline covariates. 
10.2 Sample Size Considerations 
A total of 840 subjects will be enrolled in the study and randomized in a 1:1:1 ratio to 
etanercept plus methotrexate therapy, etanercept monotherapy  and methotrexate 
monotherapy.  
To preserve the family -wise 2 -sided type one error rate at 0.05 for the multiple 
comparisons of the etanercept plus methotrexate therapy and etanercept monotherapy 
groups with methotrexate monotherapy , a Bonferroni -based gatekeepi[INVESTIGATOR_782252] ( Burman et al , 2009 and Millen et al , 2011) will be used to determine 
statistical significance for the primary and key secondary endpoints as described in 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075801] in parallel the 
primary and key secondary endpoints  (ACR 20, MDA)  for etanercept plus methotrexate 
therapy vs. methotrexate monotherapy and etanercept monotherapy vs. methotrexate 
monotherapy sequentially within each parallel path.  If one of the parallel paths rejects 
both hypotheses sequentially, and the other parallel path has at least one hypothesis not 
rejected, then unspent alpha of 0.[ADDRESS_1075802] them sequentially at a level of 0.05. 
The sample size is based on the adequacy to evaluate the efficacy of etanercept monotherapy compared with methotrexate monotherapy as measured by [CONTACT_782284] 20 response at week 24 at a significance level of 0.025 based on the Bonferroni -based gatekeepi[INVESTIGATOR_782253]. 
There are no published studies of etanercept monotherapy versus methotrexate 
monotherapy for the treatment of PsA.  Therefore for the purpose of this study the  
assumed response rates for ACR 20 for the etanercept monotherapy and methotrexate 
monotherapy arms are derived from separate studies.  In the etanercept PsA pi[INVESTIGATOR_6921] 3 study (20021630 Study) the ACR 20 response rate at week 24 was 50
% for the 
etanercept arm.  However, subjects were allowed to be on a stable dose of methotrexate at study entry.  Assuming a methotrexate naÃ¯ve population would respond better, the response rate for the etanercept monotherapy arm in this planned phase 3 study is assumed to be 60
%. 
In a recent randomized placebo-controlled trial of methotrexate monotherapy in PsA 
(Kingsley et al , 2012) the ACR 20 response rate for the methotrexate monotherapy arm 
was 34%.  However, the dose of methotrexate was 15 mg QW.  Assuming a higher dose 
of methotrexate (ie, 20 mg QW) would yield better responses, the response rate for the 
methotrexate monotherapy arm in this planned phase 3  study is assumed to be 44 %. 
Therefore, in order to detect a difference of 16% between the etanercept monotherapy 
and methotrexate monotherapy arms, using a two-sided Chi -square test at a significance 
level of 0.025 and 90 % marginal power, each treatment arm will have approximately 
280 subjects adjusting for an anticipated 10 % dropout. 
This sample size will provide marginal power > 90% to detect a treatment difference in 
ACR 20 response at week 24 between the etanercept plus methotrexate therapy  arm 
and the methotrexate monotherapy arm at a two -sided 0.025 significance level.  As 
previously mentioned, the ACR response rate at week 24 is assumed to be 44 % for the 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075803] 2016  Page 54 of 76 
CONFIDENTIAL    methotrexate monotherapy arm.  The ACR response rate at week 24 for the etanercept 
plus methotrexate therapy  arm is assumed to be 5 % higher than the etanercept 
monotherapy arm (ie, 65%).  This is based on a longitudinal observational study 
assessing the role of TNF-inhibitor plus methotrexate combination therapy versus TNF-inhibitor monotherapy (Fagerli et al, 2014 ). 
In addition, this sample size will provide marginal power >  90
% to detect treatment 
differences in MDA response at week 24 between both etanercept arms and the methotrexate arm at a two-sided 0.025 significance level, assuming response rates of 15
%, 30%, and 35 % for the methotrexate monotherapy, etanercept monotherapy, and 
etanercept plus methotrexate therapy arms, respectively.  In recent PsA trials, the MDA 24-week response rates for the placebo arm range from 3 to 7
% (Coates et al , 2010a ; 
Kavanaugh et al , 2013).  Therefore, for the methotrexate monotherapy arm, the 
response rate is assumed to be higher at 15 %.  In the pi[INVESTIGATOR_30338] 3 randomized 
placebo-controlled trial of etanercept in PsA, the MDA response rate for the etanercept monotherapy arm is estimated to be approximately 20
% at week 24 (d ata on file).  For a 
methotrexate naÃ¯ve population, the response rate is assumed to be higher at 30 %.  In 
addition, the etanercept plus methotrexate therapy arm is assumed to have a 5
% improvement over the etanercept monotherapy arm.  
10.[ADDRESS_1075804] access to unblinded information until the study is 
formally unblinded.  Unblinding and potentially unblinding information should not be 
distributed to the study team, investigators or subjects prior to the study being formally unblinded (eg, the formal unblinding may occur at the final analysis rather than during the primary analysis) except as specified (eg, Section 5.2, Section 9.2.2 and Statistical 
Analysis P lan [SAP]). 
10.[ADDRESS_1075805]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075806] will be tested 
using a Bonferroni -based gatekeepi[INVESTIGATOR_782253] (Burman et al , 2009 and 
Millen  et al, 2011) as described in Section 10.5.2 to control the fami ly-wise 2 -sided type 
one error rate at 0.05.  Between-treatment comparisons will be made using the stratified Cochran-Mantel -Haenszel (CMH) test with  baseline BMI and prior non-biologic DMARD 
use as the stratification factors.  Missing data will be imputed using non-responder 
imputation for the primary analysis. 
For other efficacy endpoints, the significance level will be 0.[ADDRESS_1075807]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075808] 2016  Page 56 of 76 
CONFIDENTIAL    groups with methotrexate monotherapy  across the primary and key secondary 
endpoints, the hypotheses will be tested using a Bonferroni -based gatekeepi[INVESTIGATOR_782252] ( Burman et al , 2009 and Millen et al , 2011) as shown in Figure [ADDRESS_1075809] in parallel the primary and key secondary 
endpoints (ACR 20, MDA) for etanercept plus methotrexate therapy vs. methotrexate monotherapy and etanercept monotherapy vs. methotrexate monotherapy sequentially within each parallel path.  If one of the parallel paths rejects both hypotheses 
sequentially, and the other parallel path has at least one hypothesis not rejected, then 
unspent alpha of 0.[ADDRESS_1075810] them sequentially at a level of 0.05.  For example, suppose the 
nominal p-values for hypotheses A1, B1, A2, and B2 ( Figure 1 ) are 0.01, 0.02, 0.03, and 
0.055, respectively.  In the first round of testing, hypotheses A1 and B1 are rejected, 
whereas hypotheses A2 and B2 are not rejected.  However, since both hypotheses A1 
and B1 are rejected, the procedure gives a second chance to re-test hypotheses A2 and 
B2 (according to the left arm of the figure) at a lower threshold of 0.[ADDRESS_1075811]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075812] 2016 Page 57 of 76 
CONFIDENTIALFigure 1.  Bonferroni-based Gatekeepi[INVESTIGATOR_782254]: Etanercept; MTX: Methotrexate 
For the primary analysis of the primary and key secondary endpoints, missing data will 
be imputed as nonresponder.  Sensitivity analyses using ob
served data and using last 
observation carried forward imputation will also be performed. Hypothesis A1:  No treatment 
difference in proportions of     
ACR 20 responders between    
ETN plus MTX and MTX groups    
(2-sided, Î±=0.025)       Hypothesis A2: No treatment 
difference in proportions of     
MDA responders between      
ETN plus MTX and MTX groups    
(2-sided, Î±=0.025)       
Hypothesis B1:  No treatment 
difference in proportions of     
ACR 20 responders between    
ETN and MTX groups      
(2-sided, Î±=0.025)       Hypothesis B2:  No treatment 
difference in proportions of     
MDA responders between      
ETN and MTX groups      
(2-sided, Î±=0.025)       
Hypothesis A2 Retested:      
No treatment difference in 
proportions of MDA responders 
between ETN plus MTX and 
MTX groups        
(2-sided, Î±=0.05)        
Hypothesis B2 Retested:      
No treatment difference in 
proportions of MDA responders 
between ETN and MTX groups     
(2-sided, Î±=0.05)        Hypothesis A1 Retested:      
No treatment difference in 
proportions of ACR 20 
responders between ETN plus 
MTX and MTX groups      
(2-sided, Î±=0.05)        
Hypothesis B1 Retested:      
No treatment difference in 
proportions of ACR 20 
responders between ETN and 
MTX groups        
(2-sided, Î±=0.05)        
  Null hypothesis is rejected         Null hypothesis is not rejected     
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075813] based on Common Toxicity 
Criteria relative to baseline will be tabulated by [CONTACT_1570] (as described in the 
SAP). 
11. REGUL ATORY OBLIGATIONS  
11.1 Informed Consent 
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the template are to 
be communicated formally in writing from the [COMPANY_010] Global Clinical  Trial Manager to 
the investigator.  The written informed consent document is to be prepared in the 
language(s) of the potential patient population.  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075814]â€™s participation in the clinical study, the investigator is responsible for 
obtaining written informed consent from the subject after adequate explanation of the 
aims, methods, anticipated benefits, and potential hazards of the study and before any 
protocol -specific screening procedures or any investigational product(s) is/are 
administered. 
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subjectâ€™s participation in the clinical study.  If the subject agrees to such 
notification, the investigator is to inform the subjectâ€™s primary care physician of the 
subjectâ€™s participation in the clinical study.  If the subject does not have a primary care physician and the i nvestigator will be acting in th at capacity, the investigator is to 
document such in the subjectâ€™s medical record.  
The acquisition of informed consent and the subjectâ€™s agreement or refusal of his/her notification of the primary care physician is to  be documented in the subjectâ€™s medical  
records, and the informed consent form  is to be signed and personally dated by [CONTACT_177157].  The original 
signed informed consent form is to be retained in accordance with institutional polic y, 
and a copy of the signed consent form is to be provided to the subject.  
11.[ADDRESS_1075815]/Independent  Ethics Committee 
A copy of the protocol, proposed informed consent form, other written subject 
information, and any proposed advertising material must be submitted to the IRB/IEC  for 
written approval.  A copy of the written approval of the protocol and informed consent 
form must be received by [CONTACT_33259].  
The investigator must submit and, where necessary, obtain approval from the IRB/IEC  
for all subsequent protocol amendments and changes to the informed consent document.  The investigator is to notify the IRB/IEC of deviations from the protocol or 
serious adverse events occurring at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedures. 
The investigator is responsible for obtaining annual IRB/IEC  approval/renewal 
throughout the duration of the study.  Copi[INVESTIGATOR_1093] i nvestigatorâ€™s reports and the 
IRB/IEC  continuance of approval must be sent to [COMPANY_010].  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075816]â€™s confidentiality is maintained for 
documents submitted to [COMPANY_010].  
â€¢ Subjects are  to be identified by a unique subject identification number . 
â€¢ Where permitted, date of birth is to be documented and formatted in accordance with 
local laws and regulations . 
â€¢ On the CRF demographics page, in addition to the unique subject identification 
number, include the age at ti me of enrollment. 
â€¢ For s erious adverse events reported to [COMPANY_010], subjects are to be identified by [CONTACT_21969] , initials  (for faxed reports, in accordance with 
local laws and regulations), and date of birth (in accordance with local laws and 
regulations ). 
â€¢ Documents that are not submitted to [COMPANY_010] (eg, signed informed consent forms) are 
to be kept in confidence by [CONTACT_093] , except as described below. 
In compliance with Federal regulations/ICH GCP Guidelines, it is required that the 
investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC  direct access to review the subjectâ€™s original 
medical records for verification of study-related procedures and data.  Di rect access 
includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study.  The investigator is obligated to inform and 
obtain the consent of the subject to permit such individual s to have access to his/her 
study -related records, including personal information. 
11.4 Investigator Signatory Obligations 
Each clinical study report is to be signed by [CONTACT_1720], in the case of 
multi -center studies, the coordinating investigator . 
The c oordinating investigator, identified by [CONTACT_11337], will be any or all of the following:  
â€¢ a recognized expert in the therapeutic area 
â€¢ an Investigator who provided significant contributions to either the design or 
interpretation of the study  
â€¢ an Investigator contributi ng a high number of eligible subjects 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
12.[ADDRESS_1075817] be obtained.  The 
IRB/IEC  must be informed of all amendments and give approval.  The investigator must  
send a copy of the approval letter from the IRB/IEC to [COMPANY_010]. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075818] 2016  Page 61 of 76 
CONFIDENTIAL    [COMPANY_010] reserves the right to terminate the study at any time.  Both [COMPANY_010] and the 
Investigator reserve the right to terminate the Investigator â€™s participation in the study 
according to the study contract.  The investigator is to notify the IRB/IEC  in writing of the 
studyâ€™s completion or early termination and send a copy of the notification to [COMPANY_010]. Subjects may be eligible for continued treatment with [COMPANY_010] investigational product(s) by [CONTACT_21970]â€™s regulatory mechanism.  However, [COMPANY_010] reserves the unilateral right, at its sole discretion, to determine 
whether to supply [COMPANY_010] investigational product (s) and by [CONTACT_21971], after 
termination of the study and before the product(s) is /are available commercially.  
12.[ADDRESS_1075819] of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the [COMPANY_010] Delegation of Authority Form.  
Source documents are original documents, data, and records from which the subjectâ€™s 
CRF data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.  
In this study, the IXRS  system captures the following data points and these are 
considered source data:  subject identification number  and randomization number 
among others. CRF entries may be considered source data if the CRF is the site of the original recording (ie, there is no other written or electronic record of data).  In this study, 
electronic PROs may be considered source documents. 
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for 
inspection at any time by [CONTACT_21972]/or appl icable regulatory 
authorities.  
Elements to include:  
â€¢ Subject files containing completed CRFs , informed consent forms, and subject 
identification list  
â€¢ Study files containing the protocol with all amendments, Investigator â€™s Brochure, 
copi[INVESTIGATOR_21892], and all correspondence to and from the IRB/IEC  
and [COMPANY_010]  
â€¢ Investigational product- related correspondence including Proof of Receipts , 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), Final Investigational Product Reconciliation Statement, as 
applicable. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075820] be 
maintained and be readily available. 
Retention of study documents will be governed by [CONTACT_782285]. 
12.3 Study Monitoring and Data Collection 
The [COMPANY_010] representative(s) and regulatory authority inspectors are responsible for 
contact[CONTACT_21974], 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected. 
The c linical monitor is responsible for verifying the CRFs at regular intervals throughout 
the study to verify adherence to the protocol; completeness, accuracy, and consistency 
of the data; and adherence to local regulations on the conduct of clinical research.  The clinical mo nitor is to have access to subject medical records and other study -related 
records needed to verify the entries on the CRFs. 
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are resolved. In accordance with ICH GCP and the sponsorâ€™s audit plans, this study may be selected for audit by [CONTACT_21975]â€™s Global R&D Compliance and Audit function 
(or designees).  Inspection of site facilities (eg, pharmacy, protocol -required therapy 
storage areas, laboratories) and review of study -related records will occur to evaluate 
the study conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
Data capture for this study is planned to be electronic:  
â€¢ All source documentation supporting entries into the CRFs must be maintained and 
readily available. 
â€¢ Updates to CRFs will be automatically documented through the softwareâ€™s â€œaudit trailâ€. 
â€¢ To ensure the quality of clinical data across all subjects and sites, a clinical data management review is performed on subject data received at [COMPANY_010].  During this 
review, subject data are checked for consistency, omissions, and any apparent 
discrepancies.  In addition, the data are reviewed for adherence to the protocol and 
GCP.  To resolve any questions arising from the clinical data management review 
process, data queries and/or site notifications are created in the EDC system 
database for site resolution and subsequently closed by [CONTACT_21976]. 
â€¢ The i nvestigator signs only the Investigator Verification Form for this EDC study.  
This signature [CONTACT_214932] s that the investigator inspected or reviewed the data on the 
CRF, the data queries, and the site notifications, and agrees with the content. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075821] 2016  Page 63 of 76 
CONFIDENTIAL    [COMPANY_010] (or designee) will perform self-evident corrections to obvious data errors in the 
clinical trial database, as documented in the Study Specific Self-Evident Corrections 
Plan.  Examples of obvious data errors that may be corrected by [CONTACT_11337] (or designee) 
include deletion of obvious duplicate data (eg, same results sent twice with the same 
date with different visit- week 4 and early termination) and clarifying â€œother, specifyâ€ if 
data are provided (eg, race, physical examination).  Each investigative site will be provided a list of the types of corrections applied to study data at the initiation of the trial 
and at study closeout.  
12.4 Investigator Responsibilities for Data Collection 
The i nvestigator is responsible for comply ing with the requirements for all assessments 
and data collection (including subjects not receiving protocol -required therapi[INVESTIGATOR_014]) as 
stipulated in the protocol for each subject in the study.  For subjects who withdraw prior 
to completion of all protocol -required visits and are unabl e or unwilling to continue the 
Schedule of Assessments (Table 1 ), the investigator can search publically available 
records (where permitted) to ascertain survival status.  This ensures that the data set(s) 
produced as an outcome of the study is/are as comprehensive as possible. 
12.[ADDRESS_1075822] be completed in English.  TRADENAMES
Â® (if used) for concomitant medications may be 
entered in the local language. 
12.6 Publication Policy  
Authorship of any publications resulting from this study will be determined on the basis of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International Committee of Medical Journal Editors ), which states:  
â€¢ Authorship credit should be based on (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically for important intellectual content; (3) final approval of the 
version to be published; (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  Authors should meet conditions 1, 2, 3 
and 4. 
â€¢ When a large, multicenter group has conducted the work, the group should identify 
the individuals who accept direct responsibility for the manuscript.  These individuals should fully meet the criteria for authorship defined above. 
â€¢ Acquisition of funding, collection of data, or general supervision of the research 
group, alone, does not justify authorship. 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075823] 2016  Page 64 of 76 
CONFIDENTIAL    â€¢ All persons designated as authors should qualify for authorship, and all those who 
qualify should be listed.  
â€¢ Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to [COMPANY_010] for review.  The Clinical Trial 
Agreement among the institution, investigator, and [COMPANY_010] will detail the procedures for, 
and timing of, [COMPANY_010]â€™s review of publications.  
12.[ADDRESS_1075824]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075825] 2016 Page 65 of 76 
CONFIDENTIAL   13. REFERENCES 
Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for 
dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab 
Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum . 
2005a;52:1227â€“1236. 
Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of 
psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis . 2005b;64:1150â€“1157. 
Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. 
Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol. 
1989;146(Suppl):69-71. 
Burman CF, Sonesson C, Guilbaud O. A recycling framework for the construction of 
Bonferroni-based multiple tests. Stat.Med. 2009; 28:739â€“761. 
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic 
arthritis: a proposed objective target for treatment. Ann Rheum Dis.  2010a;69:48-53.  
Coates L.C. Helliwell P.S. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res . 2010b; 62:965-969. 
Espi[INVESTIGATOR_103881] L, Zakraoui L, Espi[INVESTIGATOR_782255], et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J. Rheum . 1992;19:872-877. 
Fagerli KM, Lie E, van der Heidje D,  et al. The role of methotrexate co-medication in 
TNF-inhibitor treatment in patients with ps oriatic arthritis: results from [ADDRESS_1075826] study. Ann Rheum Dis . 2014;73:132â€“137. 
GÃ¼mÃ¼ ÅŸel M, Ã–zdemir M, Mevlito ÄŸlu I, Bodur S. Evaluation of the efficacy of methotrexate 
and cyclosporine therapi[INVESTIGATOR_782256]: a one-blind, randomized study.  J Eur 
Acad Dermatol Venereol . 2011;25:1080-1084. 
Kavanaugh A, McInnes IB, Mease PJ, et al. Impac t of persistent minimal disease activity 
on long-term outcomes in psoriatic arthritis:  results from [ADDRESS_1075827]. Presented at the 
ACR/ARHP Annual Meeting, [ADDRESS_1075828] 2013. 
Kingsley GH, Kowalcyzk A, Taylor H, et al. A randomized placebo-controlled trial of 
methotrexate in psoriatic arthritis. Rheumatology.  2012;51:1368-[ADDRESS_1075829] of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-681. 
Koo J. Population-based epi[INVESTIGATOR_198044]. Dermatol Clin . 1996;14:485-496. 
Mease P, Collier D, Saunders KC, et al. Biologic therapy, time to low disease activity, and effect of mono vs. background oral DM ARD therapy among psoriatic arthritis 
patients in a US registry. Ann Rheum Dis.  2013;72(suppl 3):671. 
Millen B, Dmitrienko A. Chain procedures: a cl ass of flexible closed testing procedures 
with clinical trial applications. Statistics in Biopharmaceutical Research  2011;3:14â€“30. 
Ortonne JP, Paul C, Berardesca E, et al.  A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.  Br J Dermatol.  2013;168:1080-1087.  
Product:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075830] 2016 Page 66 of 76 
CONFIDENTIAL   Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J 
Rheumatol. 1984;23:246-250. 
Shbeeb M., Uramoto KM, Gibson LE, et al. The epi[INVESTIGATOR_782257], Minnesota, [LOCATION_003], 1982-1991. J. Rheum. 2000;27:1247-1250. 
Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept re gimens for 
treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind 
multicentre trial. BMJ. 2010;340:c147. 
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and 
Research (CBER). Guidance for industry. Drug induced liver injury: premarketing clinical 
evaluation. July 2009. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf 
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075831]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075832] 2016  Page 68 of 76 
CONFIDENTIAL    Appendix A .  Additional Safety Assessment Information 
As noted in Section Adverse Event Grading Scale  
The Common Toxicity  Criteria Version 4.0 is available at the following link: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
General [LOCATION_002] Food and Drug Administration Guidance on Hepatotoxicity 
Stoppi[INVESTIGATOR_53359] 
6.4, a Food and Drug Administration Guidance exists for 
drug-induced liver injury (DILI).  This guidance is general for all investigational and 
marketed products, and is synopsized here as a reference.  It provides criteria for reporting, monitoring, and withholding investigational product in the event that a subject 
develops signs or symptoms of hepatotoxicity during a clinical trial.  
Criteria for Permanent Withholding of Investigational Product due to Potential 
Hepatotoxicity  
Investigational product should be discontinued permanently and the subject should be 
followed for possible drug-induced liver injury, if ALL of the criteria below are met: 
â€¢ TBL >  [ADDRESS_1075833] or international normalized ratio > 1.5 
â€¢ AND increased AST or ALT from the relevant bas eline value as specified below: 
Baseline AST or ALT value  AST or ALT elevation  
â‰¤ 1.[ADDRESS_1075834]  > [ADDRESS_1075835]  
â€¢ AND no other cause for the combination of laboratory abnormalities is 
immediately apparent; important potential causes for abnormal AST/ALT or TB L 
values include, but are not limited to the following: 
â€¢ obstructive gall bladder or bile duct disease  
â€¢ viral or alcoholic hepatitis (eg, hepatitis A/B/C/D/E, Epstein-Barr virus, 
cytomegalovirus, herpes simplex virus, varicella)  
â€¢ progression of malignancy involving the liver (note that metastatic disease to the 
liver, by [CONTACT_5071], should not be used as an explanation for significant AST/ALT 
elevations)  
â€¢ hypoxic or ischemic hepatopathy or congestive hepatopathy in association with 
significant right-sided heart failure  
â€¢ concomi tant administration of other hepatotoxins, including drugs that inhibit 
bilirubin glucuronidation (eg, indinavir, atazanavir, irinotecan) or herbal or dietary supplements  
â€¢ heritable disorders causing impaired glucuronidation (eg, Gilbertâ€™s syndrome); 
alpha-one antitrypsin deficiency  
â€¢ autoimmune hepatitis  
â€¢ nonalcoholic steatohepatitis or other â€œfatty liver diseaseâ€  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075836] should be evaluated for drug-induced liver injury:  
â€¢ Elevation of either AST or ALT according to the following schedule:  
Baseline AST or 
ALT value  AST or ALT elevation  
Any > [ADDRESS_1075837] at any time 
Any > [ADDRESS_1075838] but < [ADDRESS_1075839] for â‰¥ 2 weeks  
Any > [ADDRESS_1075840] but < [ADDRESS_1075841] and unable to adhere to enhanced monitoring 
schedule  
â€¢ OR:  clinical signs or symptoms that are, in the opi[INVESTIGATOR_871], 
consistent with hepatitis (such as right upper quadrant pain/tenderness, fever, 
nausea, vomiting, jaundice, rash or eosinophilia >  5%).  If such signs or 
symptoms are coupled with ALT or AST elevations >  [ADDRESS_1075842] should be withheld. 
â€¢ OR:  TBL > [ADDRESS_1075843] at any  time 
â€¢ OR:  ALP > [ADDRESS_1075844]:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075845] 2016  Page 70 of 76 
CONFIDENTIAL    Drug -induced Liver Injury Reporting & Additional Assessments  
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or  ALT 
and TBL according to the criteria specified in Section Reporting  
6.4 ([ADDRESS_1075846]/ALT and 
[ADDRESS_1075847] for TBL)  require the following: 
â€¢ The event is to be reported to [COMPANY_010] as a serious adverse event within 24 hours of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded)  
â€¢ The appropriate CRF (eg, Adverse Event CRF) that captures information necessary 
to facilitate the evaluation of treatment-emergent liver abnormalities is to be 
completed and sent to the [COMPANY_010].  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Section 9.2.2.  
â€¢ Repeat AST, ALT, ALP and bilirubin (total and direct) within [ADDRESS_1075848](s) or protocol -required therapi[INVESTIGATOR_33217]/are 
withheld (either permanently or conditionally) due to potential DILI as specified above or 
who experience AST or ALT elevations >  [ADDRESS_1075849] are to undergo a period of â€œclose 
observationâ€ until abnormalities return to normal or to the subjectâ€™s baseline levels.  
Assessments that are to be performed during this period include: 
â€¢ In cases of TBL >  2x ULN retesting of liver tests, bilirubin (total and direct) is to be 
performed every [ADDRESS_1075850](s) or protocol -required therapi[INVESTIGATOR_33218]/have been 
discontinued AND the subject is asymptomatic  
â€¢ Initiate investigation of alternative causes for elevated AST or ALT and/or elevated 
TBL: 
â—‹ Obtain complete blood count with differential to assess for eosinophilia 
â—‹ Obtain serum total immunoglobulin IgG, Anti -nuclear antibody, 
Anti Smooth Muscle Antibody, and Liver Kidney Microsomal antibody 1 to 
assess for autoimmune hepatitis  
â—‹ Obtain serum acetaminophen (paracetamol) levels 
â—‹ Obtain a more detailed history of: 
âˆ’ Prior and/or concurrent diseases or illness 
âˆ’ Exposure to environmental and/or industrial chemical agents  
Product:  Etanercept  
Protocol Number:  2 0130207  
Date:  [ADDRESS_1075851] 2016  Page 71 of 76 
CONFIDENTIAL    âˆ’ Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity -type reactions, fatigue, nausea, vomiting and 
fever  
âˆ’ Prior and/or concurrent use of alcohol, recreational drugs and 
special diets  
âˆ’ Concomitant use of medications (including non-prescription medicines and herbal and dietary supplements), plants, and mushrooms  
â—‹ Obtain viral serologies 
â—‹ Obtain CPK, haptoglobin, LDH, and peripheral blood smear  
â—‹ Perform appropriate liver imaging if clinically indicated 
â—‹ Obtain appropriate blood sampling for pharmacokinetic analysis if this has 
not already been collected  
â—‹ Obtain hepatology consult (liver biopsy may be considered in consultation 
with an hepatologist)  
â—‹ Follow the subject and the laboratory tests (ALT, AST, TBL) until all 
laboratory abnormalities return to baseline or normal.  The â€œclose 
observation periodâ€ is to continue for a minimum of [ADDRESS_1075852](s) and protocol -required 
therapi[INVESTIGATOR_014].  
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must be captured in corresponding CRFs. 
Product:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075853]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075854]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075855]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075856]:  Etanercept 
Protocol Number:  20130207 
Date:  [ADDRESS_1075857]:  Etanercept 
Protocol Number:  20130207  
Date:  [ADDRESS_1075858] 2016  Page 1 of 7 
CONFIDENTIAL    Amendment 3 
Protocol Title:  A Multicenter Double-blind, Randomized Controlled Study of 
Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With 
Psoriatic Arthritis  
 
[COMPANY_010] Protocol Number (Etanercept) 20130207 
 
Amendment 1: 
Superseding Amendment 1: 
Amendment 2: Amendment 3: [ADDRESS_1075859] 2016 
 
Rationale:  
Updated CTCAE grading version to 4.[ADDRESS_1075860] recent version and added 
â€œconfirmatory reflex testing by [CONTACT_782286] -B positive c ore 
antibody.â€ and removed the â€œin order to confirm viral load is not detectedâ€ language.  
3URGXFW(WDQHUFHSW
3URWRFRO1XPEHU'DWH$XJXVW 3DJHRI
&21),'(17,$/  'HVFULSWLRQRI&KDQJHV
6HFWLRQ*OREDO
5HSODFH
2FWREHU
:LWK
$XJXVW 
6HFWLRQ7LWOH3DJH
.H\6SRQVRU&RQWDFWV5HSODFH
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$
7HOHSKRQHHPDLO
:LWK
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$
7HOHSKRQHHPDLO
6HFWLRQ7LWOH3DJH
$GGHG
$PHQGPHQW $XJXVW
6HFWLRQ6WXG\*ORVVDU\
$GGHG
+%9 +HSDWLWLV%YLUXV
3&5 3RO\PHUDVHFKDLQUHDFWLRQ[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Product:  Etanercept 
Protocol Number:  20130207  
Date:  [ADDRESS_1075861] 2016  Page 3 of 7 
CONFIDENTIAL    Section:  5.[ADDRESS_1075862]:  
The investigator is strongly encouraged to contact [CONTACT_782287]â€™s treatment assignment. 
With: 
The investigator is strongly encouraged to contact [CONTACT_782288]â€™s treatment assignment. 
Product:  Etanercept 
Protocol Number:  20130207  
Date:  [ADDRESS_1075863] 2016  Page 4 of 7 
CONFIDENTIAL    Section:  7.[ADDRESS_1075864]:  
 30-day 
Screening Treatment Period Disease Assessment (DA) 30-day 
Follow-Up 
Weeks  0 (day 1) 4 8 12 16 24 36 48/ET DA Visite DA Follow-upe Safety (EOS)g 
GENERAL & SAFETY ASSESSMENTS              
 
Hepatitis B surface antigen & core antibody; Hepatitis C virus 
antibody X            
With: 
 30-day 
Screening Treatment Period Disease Assessment (DA) 30-day 
Follow-Up 
Weeks  0 (day 1) 4 8 12 16 24 36 48/ET DA Visite DA Follow-upe Safety (EOS)g 
GENERAL & SAFETY ASSESSMENTS              
 
Hepatitis B surface antigen & core antibody; Hepatitis C virus antibody
i X            
Product:  Etanercept 
Protocol Number:  20130207  
Date:  [ADDRESS_1075865] 2016  Page 5 of 7 
CONFIDENTIAL    Section:  7.1 Schedule of Assessments 
Table Abbreviations Added: 
HBV: hepatitis B virus; PCR: polymerase chain reaction;  
Section:  7.1 Schedule of Assessments 
Footnote i Added: 
i At screening if the subject is positive for hepatitis B core antibody, the 
confirmatory reflex testing will be performed using HBV DNA PCR.  
Section:  7.2.1 Screening Sentence 6 Added: 
At screening if the subject is positive for hepatitis B core antibody, the 
confirmatory reflex testing will be performed using hepatitis B virus (HBV) DNA 
polymerase chain reaction (PCR) . 
Product:  Etanercept 
Protocol Number:  20130207 Date:  [ADDRESS_1075866] 2016 Page 6 of 7 
CONFIDENTIAL   Section:  7.[ADDRESS_1075867]: 
Chemistry  
Sodium 
Potassium Chloride Bicarbonate 
Total protein 
Albumin Calcium 
Adjusted calcium 
Magnesium Phosphorus 
Glucose 
BUN or Urea Creatinine 
Uric acid 
Total bilirubin Direct bilirubin 
Alkaline phosphatase 
LDH AST (SGOT) 
ALT (SGPT) Urinalysis
 
Specific gravity 
pH Blood 
Protein 
Glucose Bilirubin Microscopic (Reflex 
testing if > trace) Hematology
 
WBC 
Absolute neutrophil 
count 
RBC 
Hemoglobin 
Hematocrit MCV 
MCH 
MCHC RDW 
Reticulocytes 
Platelets WBC Differential 
ï‚· Bands/stabs 
ï‚· Eosinophils 
ï‚· Basophils 
ï‚· Lymphocytes 
ï‚· Neutrophils 
ï‚· Monocytes Other Labs
 
Serum beta hCGa 
Hepatitis B surface 
antigen and Hepatitis 
B core antibody 
Hepatitis C virus 
antibody 
High sensitivity 
C-reactive protein 
Tuberculosis Testingb 
With: 
Chemistry  
Sodium Potassium 
Chloride Bicarbonate 
Total protein Albumin 
Calcium 
Adjusted calcium Magnesium 
Phosphorus 
Glucose BUN or Urea 
Creatinine 
Uric acid Total bilirubin 
Direct bilirubin 
Alkaline phosphatase LDH 
AST (SGOT) 
ALT (SGPT) Urinalysis
 
Specific gravity pH 
Blood 
Protein Glucose 
Bilirubin 
Microscopic (Reflex 
testing if > trace) Hematology
 
WBC 
Absolute neutrophil 
count 
RBC 
Hemoglobin Hematocrit 
MCV 
MCH MCHC 
RDW 
Reticulocytes Platelets 
WBC Differential 
ï‚· Bands/stabs 
ï‚· Eosinophils 
ï‚· Basophils 
ï‚· Lymphocytes 
ï‚· Neutrophils 
ï‚· Monocytes Other Labs
 
Serum beta hCGa 
Hepatitis B surface 
antigen and Hepatitis 
B core antibodyc 
Hepatitis C virus antibody 
High sensitivity 
C-reactive protein 
Tuberculosis Testing
b 
Product:  Etanercept 
Protocol Number:  20130207  
Date:  [ADDRESS_1075868] 2016  Page 7 of 7 
CONFIDENTIAL    Section:  7.4 Laboratory Assessments 
Table 2, footnote C  
Add: 
c At screening if the subject is positive for hepatitis B core antibody, the 
confirmatory reflex testing will be performed using HBV DNA PCR .. 
Section:  9.2.[ADDRESS_1075869]:  
The adverse event grading scale used will be the Common Toxicity Criteria Version 2. 
With: 
The adverse event grading scale used will be the Common Toxicity Criteria Version 4 . 
Section:  11.[ADDRESS_1075870]:  
Updates to the template are to be communicated formally in writing from the [COMPANY_010] 
Clinical Study  Manager to the investigator. 
With: 
Updates to the template are to be communicated formally in writing from the [COMPANY_010] 
Global Clinical Trial Manager to the investigator. 
Section:  Appendix A  
Adverse Event Grading Scale 
Replace:  
The Common Toxicity Criteria Version 2.0 is available at the following link: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-
992.pdf 
With: The Common Toxicity Criteria Version 4 .0 is available at the following link: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
Product :  Etanercept 
Protocol Number:  20130207  
Date:  30 October 2015  Page 1 of 4 
CONFIDENTIAL    Amendment 2 
Protocol Title:  A Multicenter Double-Blind, Randomized Controlled Study of 
Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With 
Psoriatic Arthritis  
 
[COMPANY_010] Protocol Number (Etanercept) [ADDRESS_1075871] Number 2014-004869-24 
 
Original Protocol:  29 July 2014 
Amendment 1 Date: 20 May 2015 
Superseding Amendment 1 Date:   09 July 2015 
Amendment 2 Date: 30 October 2015 
 
Rationale:  
The protocol is being amended to be consistent with international regulations and 
requirements. 
Product:  Etanercept 
Protocol Number:  20130207  
Date:  09 July 2015 Page 1 of 18 
CONFIDENTIAL   Superseding Amendment 1 
Protocol Title:  A Multicenter Double-Blind, Randomized Controlled Study of 
Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With 
Psoriatic Arthritis  
 
[COMPANY_010] Protocol Number (Etanercept) 20130207 
Original Protocol:  29 July 2014 
Amendment 1 Date: 20 May  2015 
Superseding Amendment 1 Date:   09 July 2015 
Rationale:  
The protocol is being amended to: 
â€¢ Provide updated pregnancy and contraception language.  Updated language for 
pregnancy and contraception became available immediately following approval of 
Amendment 1, thus, a superseding amendment to Amendment 1 was created to include the updated language.  Changes related to both Amendment 1 and 
Superseding Amendment 1 are detailed below.  Likewise, changes in bol d include all 
changes from Amendment 1 and Superseding Amendment 1.   
â€¢ Provide clarification for reporting hepatotoxicity as a serious adverse event 
â€¢ Clarify indications regarding use of etanercept in the US and Canada, and add 
medical information phone number as a reference for countries other than US and 
Canada 
â€¢ Update and clarify inclusion/exclusion criteria regarding tender and swollen joint 
counts, minimum number of weeks required for stable dosing of NSAIDs, excluded 
medications, and minimum number of mo nths since use of excluded medications.  
â€¢ Provide clarification regarding exclusion criteria to expand wording related to 
substances of abuse  
â€¢ Provide clarifications regarding joint assessments, to strengthen wording related to continuity of assessors in the study, and allowing for assessments by [CONTACT_782289]  
â€¢ Add folic acid and folinic acid dosing information 
â€¢ Add additional information regarding laboratory assessments used to determine 
subject eligibility  
â€¢ Clarify process for when inadvertent unblinding occurs 
â€¢ Provide updates  throughout to reflect the number of global participating sites  
â€¢ Clarify formulation of methotrexate used for rescue therapy  
â€¢ Add the EudraCT number  
â€¢ Update the Key Sponsor Contact 
â€¢ Provide an updated eSAE example form, pregnancy worksheet, and lactation 
worksheet 
â€¢ Make minor corrections  and clarifications  throughout 